<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-6160 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-6160</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-6160</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-123.html">extraction-schema-123</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <p><strong>Paper ID:</strong> paper-264895311</p>
                <p><strong>Paper Title:</strong> Potential Retinal Biomarkers in Alzheimer’s Disease</p>
                <p><strong>Paper Abstract:</strong> Alzheimer’s disease (AD) represents a major diagnostic challenge, as early detection is crucial for effective intervention. This review examines the diagnostic challenges facing current AD evaluations and explores the emerging field of retinal alterations as early indicators. Recognizing the potential of the retina as a noninvasive window to the brain, we emphasize the importance of identifying retinal biomarkers in the early stages of AD. However, the examination of AD is not without its challenges, as the similarities shared with other retinal diseases introduce complexity in the search for AD-specific markers. In this review, we address the relevance of using the retina for the early diagnosis of AD and the complex challenges associated with the search for AD-specific retinal biomarkers. We provide a comprehensive overview of the current landscape and highlight avenues for progress in AD diagnosis by retinal examination.</p>
                <p><strong>Cost:</strong> 0.027</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e6160.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e6160.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Aβ</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Amyloid-beta (Aβ) accumulation / Amyloid cascade hypothesis</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Extracellular accumulation of Aβ peptides (notably Aβ40 and Aβ42) proposed to initiate synaptic dysfunction and neuronal loss in AD by disrupting synapses and promoting inflammation and mitochondrial dysfunction.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>amyloid-beta / protein aggregation</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Aberrant production/clearance of Aβ leads to extracellular plaque accumulation; plaques disrupt synaptic function, trigger microglial activation and neuroinflammation, bind redox-active metals (iron, copper) increasing ROS, and interact with mitochondrial proteins (e.g. ABAD) to impair mitochondrial function.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Classic neuropathology in the brain (extracellular Aβ plaques), numerous post-mortem retinal studies reporting Aβ in inner retinal layers and RGC layer, animal models showing retinal Aβ deposition and retinal degeneration, mechanistic studies showing Aβ interacts with mitochondrial proteins and promotes ROS.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>The paper notes debate about causality (whether mitochondrial dysfunction is primary or secondary to amyloid/tau), and that some ocular tissues (e.g. lens) lacked Aβ deposits in some post-mortem studies; no definitive single-cause proof provided.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>preclinical through dementia (Aβ can accumulate decades before symptoms)</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>post-mortem human studies, transgenic animal models, mechanistic molecular studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Retinal Aβ overlaps with pathologies in other retinal diseases; presence of retinal Aβ does not by itself establish causal direction; some ocular compartments (lens) show inconsistent findings.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e6160.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Tau / pTau</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Hyperphosphorylated tau (pTau) / Neurofibrillary tangles (NFTs)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Intraneuronal aggregation of hyperphosphorylated tau into NFTs, associated with neuronal dysfunction and loss.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>tauopathy / protein aggregation</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Tau hyperphosphorylation destabilizes microtubules, forms NFTs, impairs axonal transport and mitochondrial function, contributing to neurodegeneration; retinal pTau reported in inner plexiform layer and GCL.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Brain neuropathology of NFTs established in AD; multiple post-mortem retinal studies report pTau/NFTs in retina; animal models show retinal tau accumulation preceding or paralleling brain pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Causality relative to other pathogenic processes (Aβ, mitochondrial dysfunction) remains debated; not all ocular tissues consistently show tau pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>preclinical through symptomatic stages (retinal pTau reported in peripheral retina and inner layers)</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>post-mortem human studies, transgenic animal models</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Retinal tau changes overlap with other neurodegenerative retinal disease markers; quantification and specificity for AD remain uncertain.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e6160.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Mitochondrial dysfunction</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Mitochondrial dysfunction / impaired fission–fusion and OXPHOS</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Altered mitochondrial dynamics (fission/fusion imbalance), impaired OXPHOS, and mitochondrial DNA damage reduce ATP and increase ROS, contributing to neuronal and retinal cell death.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>metabolic / mitochondrial</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Changes include reduced Drp1, increased Fis1, Aβ interaction with mitochondrial proteins (ABAD, cyclophilin D/mPTP), inhibition of electron transport chain (including cytochrome c oxidase), leading to ATP deficit and ROS overproduction.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Reports of altered mitochondrial dynamics/protein levels in AD brain, mitochondrial abnormalities in animal models, retinal metabolic studies in AD mouse models showing glucose hypometabolism and decreased glutamine synthesis, and mechanistic data linking Aβ to mitochondrial dysfunction.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Unclear whether mitochondrial dysfunction is primary or secondary to amyloid/tau pathology; paper explicitly states this remains unknown.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>early stages may be involved; implicated throughout disease progression</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>animal models, post-mortem human biochemical studies, in vitro mechanistic work</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Debated temporal ordering relative to amyloid/tau; direct clinical mitochondrial biomarkers in retina/brain are limited and not standardized.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e6160.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Oxidative stress / ROS</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Oxidative stress (reactive oxygen species overproduction)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Chronic increase in ROS that overwhelms antioxidant defenses, damaging proteins, lipids, DNA (including mtDNA) and promoting neurodegeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>oxidative stress</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Aβ and pTau promote ROS via metal binding and mitochondrial dysfunction; increased OXPHOS and inverse Warburg-like shifts can increase ROS; ROS cause oxidative damage to neuronal and glial components.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Elevated oxidative stress markers reported in AD brain and retina, experiments linking Aβ oligomers to NMDAR-mediated oxidative insults, and evidence of mtDNA mutations and reduced antioxidant (e.g., glutathione) in aged/AD tissues.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Not presented strong refuting evidence; oxidative stress may be both cause and effect so directionality is debated.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>early and progressive stages (present in early AD according to review)</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>biochemical, post-mortem, animal and in vitro studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Oxidative markers are non-specific and occur in many neurodegenerative and retinal diseases; measurement standardization is lacking.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e6160.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neuroinflammation / Microglial activation</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Microglial activation and neuroinflammation</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Activation of microglia producing pro-inflammatory cytokines and reactive species, contributing to synapse loss, propagation of pTau, and neurodegeneration.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>inflammation / immune</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Aβ plaques activate microglia which cluster around plaques, secrete IL-1β, IL-6, TNF-α and ROS, propagate pTau via exosomes, and downregulation of homeostatic microglial genes correlates with neuronal loss.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Post-mortem studies and animal models show microglial activation in brain and retina; genetic links (TREM2, ApoE) affect microglial phagocytosis and AD risk; experimental depletion/inhibition of microglial pathways alters tau propagation.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Complex role of microglia (protective and harmful states); review notes microglia not yet shown to play direct role in synapse degeneration in all contexts; causality and stage-specific effects are complex.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>reported in early and late stages; microglial changes noted in preclinical models and human disease</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>post-mortem human, animal models, genetic studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Inflammation is common across CNS diseases; distinguishing AD-specific inflammatory signatures in retina is challenging.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e6160.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vascular dysfunction / CAA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Vascular dysfunction (including cerebral amyloid angiopathy / blood–brain barrier breakdown)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Vascular pathology and blood–brain/blood–retina barrier dysfunction associated with Aβ deposition in vessel walls and altered cerebral/retinal blood flow.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>vascular</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Cerebral amyloid angiopathy and blood–brain barrier compromise facilitate inflammatory mediator entry and may contribute to Aβ accumulation; retinal vascular changes (vessel density, FAZ enlargement) mirror cerebral vascular pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Association between AD and cerebral vascular pathology described; retinal vascular changes reported via OCT-A and fundus imaging in AD patients; post-mortem and imaging studies showing microvascular abnormalities.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Vascular changes are non-specific and are also present in hypertension, diabetes, and other retinal diseases; causality vs consequence remains uncertain.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>may be detected preclinically and in MCI/dementia stages via retinal vascular imaging</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>imaging studies (OCT-A, fundus), post-mortem observations, reviews</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Retinal vascular metrics are influenced by age, race, ocular comorbidities (hypertension, diabetes), and image quality; specificity for AD is limited without multimodal correlation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e6160.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Insulin resistance / T2DM</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Insulin signaling dysfunction / Type 2 diabetes mellitus (T2DM) and 'brain insulin resistance'</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Disrupted insulin signaling in brain and retina (sometimes termed 'type 3 diabetes') proposed to impair neuronal metabolism and increase AD risk.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>metabolic / systemic (diabetes-related)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Aβ oligomers induce insulin receptor dysfunction and removal, impairing insulin receptor signaling (IRS-1 phosphorylation changes), promoting oxidative stress and synaptic loss; retinal insulin sensitivity may be disrupted, affecting Müller cells and neuronal survival.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Epidemiological associations between diabetes/diabetic retinopathy and increased AD risk; mechanistic studies showing Aβ impairs neuronal insulin receptors; intranasal insulin and GLP-1R agonists show cognitive/amyloid effects in studies.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Associations are not uniform across all studies; complexity in disentangling shared risk factors (age, vascular disease); some mechanisms are inferred from animal or small clinical trials.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>may be involved early (metabolic dysfunction precedes clinical AD in some models)</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>epidemiological cohorts, animal models, clinical pilot trials (intranasal insulin, GLP-1R agonists)</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Human epidemiological studies linking T2DM/DR to AD; sample sizes vary across studies (not enumerated here)</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Not all diabetic individuals develop AD; confounding vascular comorbidities complicate interpretation; therapeutic evidence preliminary.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e6160.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Genetic risk: TREM2 / ApoE</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Genetic risk factors: TREM2 mutations and Apolipoprotein E (ApoE)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Variants in genes such as TREM2 and ApoE alter microglial phagocytosis and lipid handling, increasing AD risk by impairing Aβ clearance and modifying inflammatory responses.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>genetic</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>TREM2 and ApoE participate in microglial clearance of apoptotic neurons and Aβ; loss-of-function or risk variants reduce clearance leading to accumulation of Aβ and altered microglial responses.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Genetic association studies linking TREM2 mutations to increased late-onset AD risk; experimental studies showing TREM2/ApoE involvement in microglial phagocytosis; ApoE is ligand for TREM2 in models.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Genetic risk contributes variably across individuals; presence of risk allele increases risk but is not deterministic; paper does not provide counter-genetic evidence.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>risk across lifespan; genetic predisposition affects preclinical risk</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>genetic association studies, mechanistic animal and cell studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Genetic risk factors explain only part of disease variance; interactions with environment and other pathologies are complex.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e6160.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Age</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Advanced age</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Age is the strongest epidemiological risk factor for sporadic AD, associated with metabolic, vascular, and proteostatic decline.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>demographic / age-related</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Aging-related dysregulation of metabolic pathways, mitochondrial function decline, accumulation of protein aggregates, and vascular changes increase vulnerability to AD pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Epidemiological data establishing age as major risk factor; many discussed mechanisms (mitochondrial dysfunction, oxidative stress) worsen with age.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>increases baseline risk across lifespan; AD prevalence rises with age</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>epidemiology and mechanistic literature</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Age is a non-modifiable risk; aging mechanisms are heterogeneous.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e6160.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Glaucoma association</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Primary open-angle glaucoma (POAG) / glaucoma association with AD</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Epidemiologic and mechanistic literature suggests shared features (RGC loss, mitochondrial dysfunction, oxidative stress) and possible increased AD risk in glaucoma patients, though evidence is mixed.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>comorbidity / association (ocular disease)</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Both diseases show RGC degeneration, mitochondrial dysfunction, oxidative stress, and possibly shared genetic factors (e.g., OPTN); glaucoma could be a predictor or share pathophysiology with AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Some cohort and registry studies (Taiwan, Korea, Canada) report increased AD risk among POAG patients; some meta-analyses and studies report positive associations (RR up to ~1.52 in a 2019 meta-analysis).</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Other studies and a 2021 meta-analysis found no association (RR 1.03 95% CI 0.93-1.05); heterogeneity (I2 high) and diagnostic differences may explain contradictions.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>association across clinical stages; RGC loss detectable via OCT in MCI/AD</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>epidemiological cohort studies, meta-analyses, mechanistic comparisons</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Varied across geographic cohorts; some studies focused on hospitalized older adults or national registries (e.g., Taiwan, Korea, Canada); specifics vary per cited study.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Conflicting epidemiological results likely due to diagnostic misclassification, cohort differences, disease severity inclusion, and study design heterogeneity.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e6160.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Diabetic retinopathy association</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Diabetic retinopathy (DR) and AD risk</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>DR and underlying diabetes are associated with increased risk of AD and cognitive impairment, possibly via impaired insulin signaling, vascular and metabolic mechanisms.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>comorbidity / metabolic</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Diabetes-linked insulin resistance, hyperglycemia, vascular damage and retinal neurodegeneration (DR) may increase AD risk via impaired brain insulin signaling, oxidative stress and inflammation.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Epidemiological studies and registry analyses report higher AD risk with diabetes and severe diabetic retinal disease; systematic reviews and meta-analyses support associations between DR and cognitive impairment.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Association not universal; complexity from shared vascular risk factors; causality not established.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>association observed in mid- to late-life diabetes cohorts; may predict future dementia risk</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>epidemiological cohorts, systematic reviews, registry-based studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Large registries and cohort studies (e.g., Danish registry, other cohorts), variable sample sizes; specific numbers not enumerated in review.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Diabetes and vascular factors confound interpretation; more longitudinal mechanistic studies needed.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e6160.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AMD association</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Age-related macular degeneration (AMD) association with AD</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>AMD shares pathological features with AD (Aβ deposits, iron accumulation, inflammation, oxidative stress) and some epidemiological studies report modest increased AD risk in AMD patients.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td>comorbidity / retinal degenerative overlap</td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td>Shared extracellular deposits (Aβ-like material), iron accumulation and chronic inflammation may reflect overlapping pathogenic mechanisms between AMD and AD.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td>Some studies show increased AD risk in AMD patients (e.g., 1.23-fold increase reported in one study); overlapping molecular features described; iron chelation and anti-Aβ strategies proposed for both.</td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td>Large UK study found no significant association between early AMD and AD; heterogeneity in studies and possible survival bias limit conclusions.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>associations considered in older adults; AMD typically in >50 years</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>epidemiological cohort studies, mechanistic comparisons</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Varied; some large cohorts (e.g., UK study of 2088 individuals aged 69–97) with mixed findings.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Heterogeneity in AMD stage definitions, survival bias, single-eye imaging limitations, and cross-sectional designs constrain causal inference.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.12">
                <h3 class="extraction-instance">Extracted Data Instance 12 (e6160.12)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Clinical diagnostic methods (brain)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Standard AD diagnostic methods: cognitive tests, MRI, PET, CSF, blood tests, genetic testing</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Established clinical and biomarker-based methods used to detect AD-related structural and molecular brain changes, but many are invasive, expensive, or detect changes late.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Cognitive testing; MRI structural imaging; PET (amyloid/tau); CSF biomarker analysis; blood biomarkers; genetic testing</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Cognitive tests assess memory/cognition; MRI assesses structural atrophy; PET visualizes Aβ/tau deposition; CSF measures Aβ/tau/phospho-tau; blood tests measure circulating biomarkers; genetic tests detect deterministic/risk variants.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Paper states neuroimaging (PET) and CSF are accurate but invasive/expensive; clinical diagnostic misclassification leads to 10–15% inaccuracy for AD diagnosis (reported); specific sensitivity/specificity numbers not given in review.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>PET/CSF can detect preclinical and prodromal pathologic changes; cognitive tests often detect later symptomatic stages</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>clinical diagnostics, guideline and review literature</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Invasiveness, high cost, limited accessibility, subjectivity of cognitive testing, lack of specificity in some biomarkers and overlap with other dementias.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.13">
                <h3 class="extraction-instance">Extracted Data Instance 13 (e6160.13)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OCT</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Optical coherence tomography (OCT)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Non-invasive imaging of retinal structure (cross-sectional 3D images) used to measure macular thickness, RNFL, GCL, and detect retinal thinning associated with AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>OCT retinal structural imaging</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Low-coherence interferometry produces high-resolution cross-sectional retinal images to quantify macular volume, RNFL and GCL thickness, and detect inner retinal layer thinning.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Numerous studies report macular and RNFL thinning in AD and high genetic-risk individuals; quantitative performance metrics (sensitivity/specificity) are not provided in the review and vary across studies; overall lacks disease specificity due to overlap with glaucoma and other diseases.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Changes reported in asymptomatic high-risk individuals, MCI, and AD dementia (preclinical to symptomatic)</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>human OCT studies, cross-sectional and some longitudinal cohorts, meta-analyses</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Studies include mild and moderate AD patients, asymptomatic high-genetic-risk subjects; sample sizes vary by cited study (examples: 39 mild AD + 21 moderate AD in one OCT color perception study).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>OCT findings lack specificity (overlap with glaucoma, AMD, diabetic retinopathy), affected by intraocular pressure, axial length, refractive error, comorbidities, race, age and gender; measurement variability across devices/platforms.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.14">
                <h3 class="extraction-instance">Extracted Data Instance 14 (e6160.14)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OCT-A</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Optical coherence tomography angiography (OCT-A)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Non-invasive angiographic imaging of retinal microvasculature (no contrast) used to detect microvascular changes associated with AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>OCT angiography (OCT-A)</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Captures motion contrast from blood flow to map retinal capillary networks, enabling measurement of vessel density, foveal avascular zone (FAZ) size and microvascular density in superficial and deep plexuses.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Studies show FAZ enlargement and reduced macular/foveal vascular density in AD versus controls; quantitative sensitivity/specificity not reported in review; affected by image quality and ocular/ systemic comorbidities.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>May detect microvascular changes prior to clinical symptoms (preclinical / early stages) and in symptomatic AD</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>human imaging studies, systematic reviews/meta-analyses cited</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Patients with AD and control groups in cited OCT-A studies; sample sizes vary and are not uniformly reported in review.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Readings influenced by image quality, ocular anatomy, hypertension, diabetes and other eye diseases; values may be altered by race, age, gender; lack of standardization.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.15">
                <h3 class="extraction-instance">Extracted Data Instance 15 (e6160.15)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Hyperspectral imaging</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Retinal hyperspectral imaging</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Spectral-spatial imaging across many wavelengths that aims to detect spectral signatures of Aβ and other molecular changes in retina non-invasively.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Hyperspectral retinal imaging</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Acquires images across contiguous wavelengths to generate a hyperspectral cube, allowing spectral identification of molecular constituents (e.g., Aβ aggregates) in the retina.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Promising discrimination in AD mouse models and preliminary human studies showing separation of AD pathology vs controls; specific sensitivity/specificity/AUC metrics not provided; larger replication studies required.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Reported to distinguish AD-pathology positive patients and preclinical animal models (potential for early detection)</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>animal model studies and early human feasibility studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>AD mice (e.g., 5xFAD) and small human cohorts in preliminary studies; larger cohorts not yet reported in review.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Technique is emerging — needs larger replication, standardization; unknown generalizability and specificity vs other retinal pathologies.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.16">
                <h3 class="extraction-instance">Extracted Data Instance 16 (e6160.16)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Fundus photography</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Retinal fundus photography</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Two-dimensional color imaging of the retina useful for assessing vessel caliber, tortuosity and other microvascular features that may reflect AD-associated vascular changes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Fundus photography</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Captures color images of the posterior pole enabling quantification of vascular geometry (caliber, tortuosity, branching) and detection of microvascular signs linked to cerebral pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Used to detect narrower venules and more tortuous vessels in AD; review states fundus photography provides detailed images with high sensitivity and specificity for vascular features but does not provide exact diagnostic metrics for AD; best used complementarily.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Detects vascular changes potentially in preclinical and clinical stages</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>cross-sectional imaging studies and systematic reviews</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Various human cohorts; study sizes vary and are not consistently reported in review.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Not a standalone diagnostic tool; vascular changes are non-specific and can be caused by other systemic/ocular diseases; image-based measures are influenced by acquisition and analysis methods.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.17">
                <h3 class="extraction-instance">Extracted Data Instance 17 (e6160.17)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Vitreous Aβ/pTau</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Vitreous humor sampling for Aβ and phosphorylated tau</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Direct measurement of Aβ and pTau proteins in intraocular vitreous fluid, which correlates with cognitive function but requires invasive intraocular sampling.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Vitreous humor biomarker analysis</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Biochemical assays of vitreous fluid quantify Aβ and pTau concentrations which have been correlated with cognitive impairment.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Reduced Aβ and pTau levels reported and correlated with cognitive function in cited studies; exact sensitivity/specificity not provided; method is invasive (requires intraocular surgery).</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Reported correlations with cognitive impairment and AD pathology; may reflect disease state rather than early screening</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>human intraocular fluid measurement studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Patients undergoing intraocular procedures in which vitreous was sampled; sample sizes limited by surgical contexts (not specified in review).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Invasiveness makes it impractical as a screening tool; surgical risks and feasibility limit clinical applicability.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.18">
                <h3 class="extraction-instance">Extracted Data Instance 18 (e6160.18)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Lens fluorescent ligand</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Fluorescent ligand binding to Aβ in crystalline lens (eye-drop + imaging)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Topical ligand designed to bind ocular Aβ combined with laser scanning detection to visualize Aβ accumulation in the lens non-invasively.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Fluorescent ligand imaging of lens Aβ</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Apply a fluorescent ligand as an eye drop that binds Aβ, then use a scanning device to detect ligand fluorescence in the lens, which was correlated with brain measures in preliminary studies.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Exploratory studies report correlations between lens signal and brain Aβ; specific diagnostic metrics not reported; further validation ongoing.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Potential for early detection but currently exploratory</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>exploratory human trials and imaging feasibility studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Small exploratory cohorts in early studies; not specified in review.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Some post-mortem studies failed to find Aβ in lens; technique is exploratory and requires validation; may not represent whole-brain pathology.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.19">
                <h3 class="extraction-instance">Extracted Data Instance 19 (e6160.19)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CCM</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Corneal confocal microscopy (CCM)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Non-invasive high-resolution imaging of corneal nerve fibers (subbasal nerve plexus) proposed to reflect peripheral and central neurodegeneration including AD.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Corneal confocal microscopy</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>In vivo microscopy that quantifies corneal nerve morphology and density; alterations have been reported in diabetic neuropathy and other neurodegenerative diseases and may correlate with cholinergic deficits in AD.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Used successfully in peripheral neuropathy and PD/MS studies; for AD, potential signal exists but retinal-specific insight is limited; no AD-specific sensitivity/specificity reported in review.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>May detect peripheral neurodegeneration even in early disease, but AD-specific data are preliminary</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>cross-disease imaging studies, pilot studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Studies in diabetic neuropathy, Parkinson's disease, MS; AD-specific cohorts limited in review.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>CCM assesses corneal (anterior eye) nerves rather than retina; relationship to central AD pathology is indirect and requires further validation.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e6160.20">
                <h3 class="extraction-instance">Extracted Data Instance 20 (e6160.20)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of proposed causes or risk factors for Alzheimer's disease, supporting or refuting evidence, and methods for detecting Alzheimer's disease, including their effectiveness and limitations.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Pupillometry</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Pupillometry / pupillary light reflex testing</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Measurement of pupil size and dynamic light responses that may reflect autonomic and cholinergic dysfunction in AD and correlate with memory function.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Potential Retinal Biomarkers in Alzheimer's Disease</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cause_type</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>cause_description</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_for_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>evidence_against_cause</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>detection_method</strong></td>
                            <td>Pupillometry</td>
                        </tr>
                        <tr>
                            <td><strong>detection_method_description</strong></td>
                            <td>Quantitative recording of pupillary responses (size, constriction/dilation dynamics) to light stimuli as a non-invasive biomarker of autonomic/cholinergic dysfunction linked to AD.</td>
                        </tr>
                        <tr>
                            <td><strong>detection_performance</strong></td>
                            <td>Reported changes include increased pupil size and less pronounced pupillary light reflex in AD; pupillometry can distinguish some at-risk individuals but exact diagnostic metrics not provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>disease_stage_detected</strong></td>
                            <td>Reported in early risk states and symptomatic AD in some studies</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>human observational studies and biomarker feasibility research</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Human cohorts in cited studies; sample sizes vary and are not explicitly enumerated in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_or_counterpoints</strong></td>
                            <td>Pupillary measures are influenced by many factors (medications, autonomic conditions, lighting); not disease-specific and require standardized protocols.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Potential Retinal Biomarkers in Alzheimer’s Disease', 'publication_date_yy_mm': '2023-10'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>The amyloid cascade hypothesis <em>(Rating: 2)</em></li>
                <li>Microglia in Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease <em>(Rating: 2)</em></li>
                <li>Optical coherence tomography in Patients with Alzheimer's Disease: What Can It Tell Us? <em>(Rating: 2)</em></li>
                <li>Retinal Vascular Changes in Alzheimer's Dementia and Mild Cognitive Impairment: A Pilot Study Using Ultra-Widefield Imaging <em>(Rating: 1)</em></li>
                <li>Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer's disease <em>(Rating: 1)</em></li>
                <li>Intranasal insulin as a treatment for Alzheimer's disease: A review of basic research and clinical evidence <em>(Rating: 1)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-6160",
    "paper_id": "paper-264895311",
    "extraction_schema_id": "extraction-schema-123",
    "extracted_data": [
        {
            "name_short": "Aβ",
            "name_full": "Amyloid-beta (Aβ) accumulation / Amyloid cascade hypothesis",
            "brief_description": "Extracellular accumulation of Aβ peptides (notably Aβ40 and Aβ42) proposed to initiate synaptic dysfunction and neuronal loss in AD by disrupting synapses and promoting inflammation and mitochondrial dysfunction.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "amyloid-beta / protein aggregation",
            "cause_description": "Aberrant production/clearance of Aβ leads to extracellular plaque accumulation; plaques disrupt synaptic function, trigger microglial activation and neuroinflammation, bind redox-active metals (iron, copper) increasing ROS, and interact with mitochondrial proteins (e.g. ABAD) to impair mitochondrial function.",
            "evidence_for_cause": "Classic neuropathology in the brain (extracellular Aβ plaques), numerous post-mortem retinal studies reporting Aβ in inner retinal layers and RGC layer, animal models showing retinal Aβ deposition and retinal degeneration, mechanistic studies showing Aβ interacts with mitochondrial proteins and promotes ROS.",
            "evidence_against_cause": "The paper notes debate about causality (whether mitochondrial dysfunction is primary or secondary to amyloid/tau), and that some ocular tissues (e.g. lens) lacked Aβ deposits in some post-mortem studies; no definitive single-cause proof provided.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "preclinical through dementia (Aβ can accumulate decades before symptoms)",
            "study_type": "post-mortem human studies, transgenic animal models, mechanistic molecular studies",
            "study_population": null,
            "limitations_or_counterpoints": "Retinal Aβ overlaps with pathologies in other retinal diseases; presence of retinal Aβ does not by itself establish causal direction; some ocular compartments (lens) show inconsistent findings.",
            "uuid": "e6160.0",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Tau / pTau",
            "name_full": "Hyperphosphorylated tau (pTau) / Neurofibrillary tangles (NFTs)",
            "brief_description": "Intraneuronal aggregation of hyperphosphorylated tau into NFTs, associated with neuronal dysfunction and loss.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "tauopathy / protein aggregation",
            "cause_description": "Tau hyperphosphorylation destabilizes microtubules, forms NFTs, impairs axonal transport and mitochondrial function, contributing to neurodegeneration; retinal pTau reported in inner plexiform layer and GCL.",
            "evidence_for_cause": "Brain neuropathology of NFTs established in AD; multiple post-mortem retinal studies report pTau/NFTs in retina; animal models show retinal tau accumulation preceding or paralleling brain pathology.",
            "evidence_against_cause": "Causality relative to other pathogenic processes (Aβ, mitochondrial dysfunction) remains debated; not all ocular tissues consistently show tau pathology.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "preclinical through symptomatic stages (retinal pTau reported in peripheral retina and inner layers)",
            "study_type": "post-mortem human studies, transgenic animal models",
            "study_population": null,
            "limitations_or_counterpoints": "Retinal tau changes overlap with other neurodegenerative retinal disease markers; quantification and specificity for AD remain uncertain.",
            "uuid": "e6160.1",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Mitochondrial dysfunction",
            "name_full": "Mitochondrial dysfunction / impaired fission–fusion and OXPHOS",
            "brief_description": "Altered mitochondrial dynamics (fission/fusion imbalance), impaired OXPHOS, and mitochondrial DNA damage reduce ATP and increase ROS, contributing to neuronal and retinal cell death.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "metabolic / mitochondrial",
            "cause_description": "Changes include reduced Drp1, increased Fis1, Aβ interaction with mitochondrial proteins (ABAD, cyclophilin D/mPTP), inhibition of electron transport chain (including cytochrome c oxidase), leading to ATP deficit and ROS overproduction.",
            "evidence_for_cause": "Reports of altered mitochondrial dynamics/protein levels in AD brain, mitochondrial abnormalities in animal models, retinal metabolic studies in AD mouse models showing glucose hypometabolism and decreased glutamine synthesis, and mechanistic data linking Aβ to mitochondrial dysfunction.",
            "evidence_against_cause": "Unclear whether mitochondrial dysfunction is primary or secondary to amyloid/tau pathology; paper explicitly states this remains unknown.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "early stages may be involved; implicated throughout disease progression",
            "study_type": "animal models, post-mortem human biochemical studies, in vitro mechanistic work",
            "study_population": null,
            "limitations_or_counterpoints": "Debated temporal ordering relative to amyloid/tau; direct clinical mitochondrial biomarkers in retina/brain are limited and not standardized.",
            "uuid": "e6160.2",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Oxidative stress / ROS",
            "name_full": "Oxidative stress (reactive oxygen species overproduction)",
            "brief_description": "Chronic increase in ROS that overwhelms antioxidant defenses, damaging proteins, lipids, DNA (including mtDNA) and promoting neurodegeneration.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "oxidative stress",
            "cause_description": "Aβ and pTau promote ROS via metal binding and mitochondrial dysfunction; increased OXPHOS and inverse Warburg-like shifts can increase ROS; ROS cause oxidative damage to neuronal and glial components.",
            "evidence_for_cause": "Elevated oxidative stress markers reported in AD brain and retina, experiments linking Aβ oligomers to NMDAR-mediated oxidative insults, and evidence of mtDNA mutations and reduced antioxidant (e.g., glutathione) in aged/AD tissues.",
            "evidence_against_cause": "Not presented strong refuting evidence; oxidative stress may be both cause and effect so directionality is debated.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "early and progressive stages (present in early AD according to review)",
            "study_type": "biochemical, post-mortem, animal and in vitro studies",
            "study_population": null,
            "limitations_or_counterpoints": "Oxidative markers are non-specific and occur in many neurodegenerative and retinal diseases; measurement standardization is lacking.",
            "uuid": "e6160.3",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Neuroinflammation / Microglial activation",
            "name_full": "Microglial activation and neuroinflammation",
            "brief_description": "Activation of microglia producing pro-inflammatory cytokines and reactive species, contributing to synapse loss, propagation of pTau, and neurodegeneration.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "inflammation / immune",
            "cause_description": "Aβ plaques activate microglia which cluster around plaques, secrete IL-1β, IL-6, TNF-α and ROS, propagate pTau via exosomes, and downregulation of homeostatic microglial genes correlates with neuronal loss.",
            "evidence_for_cause": "Post-mortem studies and animal models show microglial activation in brain and retina; genetic links (TREM2, ApoE) affect microglial phagocytosis and AD risk; experimental depletion/inhibition of microglial pathways alters tau propagation.",
            "evidence_against_cause": "Complex role of microglia (protective and harmful states); review notes microglia not yet shown to play direct role in synapse degeneration in all contexts; causality and stage-specific effects are complex.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "reported in early and late stages; microglial changes noted in preclinical models and human disease",
            "study_type": "post-mortem human, animal models, genetic studies",
            "study_population": null,
            "limitations_or_counterpoints": "Inflammation is common across CNS diseases; distinguishing AD-specific inflammatory signatures in retina is challenging.",
            "uuid": "e6160.4",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Vascular dysfunction / CAA",
            "name_full": "Vascular dysfunction (including cerebral amyloid angiopathy / blood–brain barrier breakdown)",
            "brief_description": "Vascular pathology and blood–brain/blood–retina barrier dysfunction associated with Aβ deposition in vessel walls and altered cerebral/retinal blood flow.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "vascular",
            "cause_description": "Cerebral amyloid angiopathy and blood–brain barrier compromise facilitate inflammatory mediator entry and may contribute to Aβ accumulation; retinal vascular changes (vessel density, FAZ enlargement) mirror cerebral vascular pathology.",
            "evidence_for_cause": "Association between AD and cerebral vascular pathology described; retinal vascular changes reported via OCT-A and fundus imaging in AD patients; post-mortem and imaging studies showing microvascular abnormalities.",
            "evidence_against_cause": "Vascular changes are non-specific and are also present in hypertension, diabetes, and other retinal diseases; causality vs consequence remains uncertain.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "may be detected preclinically and in MCI/dementia stages via retinal vascular imaging",
            "study_type": "imaging studies (OCT-A, fundus), post-mortem observations, reviews",
            "study_population": null,
            "limitations_or_counterpoints": "Retinal vascular metrics are influenced by age, race, ocular comorbidities (hypertension, diabetes), and image quality; specificity for AD is limited without multimodal correlation.",
            "uuid": "e6160.5",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Insulin resistance / T2DM",
            "name_full": "Insulin signaling dysfunction / Type 2 diabetes mellitus (T2DM) and 'brain insulin resistance'",
            "brief_description": "Disrupted insulin signaling in brain and retina (sometimes termed 'type 3 diabetes') proposed to impair neuronal metabolism and increase AD risk.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "metabolic / systemic (diabetes-related)",
            "cause_description": "Aβ oligomers induce insulin receptor dysfunction and removal, impairing insulin receptor signaling (IRS-1 phosphorylation changes), promoting oxidative stress and synaptic loss; retinal insulin sensitivity may be disrupted, affecting Müller cells and neuronal survival.",
            "evidence_for_cause": "Epidemiological associations between diabetes/diabetic retinopathy and increased AD risk; mechanistic studies showing Aβ impairs neuronal insulin receptors; intranasal insulin and GLP-1R agonists show cognitive/amyloid effects in studies.",
            "evidence_against_cause": "Associations are not uniform across all studies; complexity in disentangling shared risk factors (age, vascular disease); some mechanisms are inferred from animal or small clinical trials.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "may be involved early (metabolic dysfunction precedes clinical AD in some models)",
            "study_type": "epidemiological cohorts, animal models, clinical pilot trials (intranasal insulin, GLP-1R agonists)",
            "study_population": "Human epidemiological studies linking T2DM/DR to AD; sample sizes vary across studies (not enumerated here)",
            "limitations_or_counterpoints": "Not all diabetic individuals develop AD; confounding vascular comorbidities complicate interpretation; therapeutic evidence preliminary.",
            "uuid": "e6160.6",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Genetic risk: TREM2 / ApoE",
            "name_full": "Genetic risk factors: TREM2 mutations and Apolipoprotein E (ApoE)",
            "brief_description": "Variants in genes such as TREM2 and ApoE alter microglial phagocytosis and lipid handling, increasing AD risk by impairing Aβ clearance and modifying inflammatory responses.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "genetic",
            "cause_description": "TREM2 and ApoE participate in microglial clearance of apoptotic neurons and Aβ; loss-of-function or risk variants reduce clearance leading to accumulation of Aβ and altered microglial responses.",
            "evidence_for_cause": "Genetic association studies linking TREM2 mutations to increased late-onset AD risk; experimental studies showing TREM2/ApoE involvement in microglial phagocytosis; ApoE is ligand for TREM2 in models.",
            "evidence_against_cause": "Genetic risk contributes variably across individuals; presence of risk allele increases risk but is not deterministic; paper does not provide counter-genetic evidence.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "risk across lifespan; genetic predisposition affects preclinical risk",
            "study_type": "genetic association studies, mechanistic animal and cell studies",
            "study_population": null,
            "limitations_or_counterpoints": "Genetic risk factors explain only part of disease variance; interactions with environment and other pathologies are complex.",
            "uuid": "e6160.7",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Age",
            "name_full": "Advanced age",
            "brief_description": "Age is the strongest epidemiological risk factor for sporadic AD, associated with metabolic, vascular, and proteostatic decline.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "demographic / age-related",
            "cause_description": "Aging-related dysregulation of metabolic pathways, mitochondrial function decline, accumulation of protein aggregates, and vascular changes increase vulnerability to AD pathology.",
            "evidence_for_cause": "Epidemiological data establishing age as major risk factor; many discussed mechanisms (mitochondrial dysfunction, oxidative stress) worsen with age.",
            "evidence_against_cause": null,
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "increases baseline risk across lifespan; AD prevalence rises with age",
            "study_type": "epidemiology and mechanistic literature",
            "study_population": null,
            "limitations_or_counterpoints": "Age is a non-modifiable risk; aging mechanisms are heterogeneous.",
            "uuid": "e6160.8",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Glaucoma association",
            "name_full": "Primary open-angle glaucoma (POAG) / glaucoma association with AD",
            "brief_description": "Epidemiologic and mechanistic literature suggests shared features (RGC loss, mitochondrial dysfunction, oxidative stress) and possible increased AD risk in glaucoma patients, though evidence is mixed.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "comorbidity / association (ocular disease)",
            "cause_description": "Both diseases show RGC degeneration, mitochondrial dysfunction, oxidative stress, and possibly shared genetic factors (e.g., OPTN); glaucoma could be a predictor or share pathophysiology with AD.",
            "evidence_for_cause": "Some cohort and registry studies (Taiwan, Korea, Canada) report increased AD risk among POAG patients; some meta-analyses and studies report positive associations (RR up to ~1.52 in a 2019 meta-analysis).",
            "evidence_against_cause": "Other studies and a 2021 meta-analysis found no association (RR 1.03 95% CI 0.93-1.05); heterogeneity (I2 high) and diagnostic differences may explain contradictions.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "association across clinical stages; RGC loss detectable via OCT in MCI/AD",
            "study_type": "epidemiological cohort studies, meta-analyses, mechanistic comparisons",
            "study_population": "Varied across geographic cohorts; some studies focused on hospitalized older adults or national registries (e.g., Taiwan, Korea, Canada); specifics vary per cited study.",
            "limitations_or_counterpoints": "Conflicting epidemiological results likely due to diagnostic misclassification, cohort differences, disease severity inclusion, and study design heterogeneity.",
            "uuid": "e6160.9",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Diabetic retinopathy association",
            "name_full": "Diabetic retinopathy (DR) and AD risk",
            "brief_description": "DR and underlying diabetes are associated with increased risk of AD and cognitive impairment, possibly via impaired insulin signaling, vascular and metabolic mechanisms.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "comorbidity / metabolic",
            "cause_description": "Diabetes-linked insulin resistance, hyperglycemia, vascular damage and retinal neurodegeneration (DR) may increase AD risk via impaired brain insulin signaling, oxidative stress and inflammation.",
            "evidence_for_cause": "Epidemiological studies and registry analyses report higher AD risk with diabetes and severe diabetic retinal disease; systematic reviews and meta-analyses support associations between DR and cognitive impairment.",
            "evidence_against_cause": "Association not universal; complexity from shared vascular risk factors; causality not established.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "association observed in mid- to late-life diabetes cohorts; may predict future dementia risk",
            "study_type": "epidemiological cohorts, systematic reviews, registry-based studies",
            "study_population": "Large registries and cohort studies (e.g., Danish registry, other cohorts), variable sample sizes; specific numbers not enumerated in review.",
            "limitations_or_counterpoints": "Diabetes and vascular factors confound interpretation; more longitudinal mechanistic studies needed.",
            "uuid": "e6160.10",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "AMD association",
            "name_full": "Age-related macular degeneration (AMD) association with AD",
            "brief_description": "AMD shares pathological features with AD (Aβ deposits, iron accumulation, inflammation, oxidative stress) and some epidemiological studies report modest increased AD risk in AMD patients.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": "comorbidity / retinal degenerative overlap",
            "cause_description": "Shared extracellular deposits (Aβ-like material), iron accumulation and chronic inflammation may reflect overlapping pathogenic mechanisms between AMD and AD.",
            "evidence_for_cause": "Some studies show increased AD risk in AMD patients (e.g., 1.23-fold increase reported in one study); overlapping molecular features described; iron chelation and anti-Aβ strategies proposed for both.",
            "evidence_against_cause": "Large UK study found no significant association between early AMD and AD; heterogeneity in studies and possible survival bias limit conclusions.",
            "detection_method": null,
            "detection_method_description": null,
            "detection_performance": null,
            "disease_stage_detected": "associations considered in older adults; AMD typically in &gt;50 years",
            "study_type": "epidemiological cohort studies, mechanistic comparisons",
            "study_population": "Varied; some large cohorts (e.g., UK study of 2088 individuals aged 69–97) with mixed findings.",
            "limitations_or_counterpoints": "Heterogeneity in AMD stage definitions, survival bias, single-eye imaging limitations, and cross-sectional designs constrain causal inference.",
            "uuid": "e6160.11",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Clinical diagnostic methods (brain)",
            "name_full": "Standard AD diagnostic methods: cognitive tests, MRI, PET, CSF, blood tests, genetic testing",
            "brief_description": "Established clinical and biomarker-based methods used to detect AD-related structural and molecular brain changes, but many are invasive, expensive, or detect changes late.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "Cognitive testing; MRI structural imaging; PET (amyloid/tau); CSF biomarker analysis; blood biomarkers; genetic testing",
            "detection_method_description": "Cognitive tests assess memory/cognition; MRI assesses structural atrophy; PET visualizes Aβ/tau deposition; CSF measures Aβ/tau/phospho-tau; blood tests measure circulating biomarkers; genetic tests detect deterministic/risk variants.",
            "detection_performance": "Paper states neuroimaging (PET) and CSF are accurate but invasive/expensive; clinical diagnostic misclassification leads to 10–15% inaccuracy for AD diagnosis (reported); specific sensitivity/specificity numbers not given in review.",
            "disease_stage_detected": "PET/CSF can detect preclinical and prodromal pathologic changes; cognitive tests often detect later symptomatic stages",
            "study_type": "clinical diagnostics, guideline and review literature",
            "study_population": null,
            "limitations_or_counterpoints": "Invasiveness, high cost, limited accessibility, subjectivity of cognitive testing, lack of specificity in some biomarkers and overlap with other dementias.",
            "uuid": "e6160.12",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "OCT",
            "name_full": "Optical coherence tomography (OCT)",
            "brief_description": "Non-invasive imaging of retinal structure (cross-sectional 3D images) used to measure macular thickness, RNFL, GCL, and detect retinal thinning associated with AD.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "OCT retinal structural imaging",
            "detection_method_description": "Low-coherence interferometry produces high-resolution cross-sectional retinal images to quantify macular volume, RNFL and GCL thickness, and detect inner retinal layer thinning.",
            "detection_performance": "Numerous studies report macular and RNFL thinning in AD and high genetic-risk individuals; quantitative performance metrics (sensitivity/specificity) are not provided in the review and vary across studies; overall lacks disease specificity due to overlap with glaucoma and other diseases.",
            "disease_stage_detected": "Changes reported in asymptomatic high-risk individuals, MCI, and AD dementia (preclinical to symptomatic)",
            "study_type": "human OCT studies, cross-sectional and some longitudinal cohorts, meta-analyses",
            "study_population": "Studies include mild and moderate AD patients, asymptomatic high-genetic-risk subjects; sample sizes vary by cited study (examples: 39 mild AD + 21 moderate AD in one OCT color perception study).",
            "limitations_or_counterpoints": "OCT findings lack specificity (overlap with glaucoma, AMD, diabetic retinopathy), affected by intraocular pressure, axial length, refractive error, comorbidities, race, age and gender; measurement variability across devices/platforms.",
            "uuid": "e6160.13",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "OCT-A",
            "name_full": "Optical coherence tomography angiography (OCT-A)",
            "brief_description": "Non-invasive angiographic imaging of retinal microvasculature (no contrast) used to detect microvascular changes associated with AD.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "OCT angiography (OCT-A)",
            "detection_method_description": "Captures motion contrast from blood flow to map retinal capillary networks, enabling measurement of vessel density, foveal avascular zone (FAZ) size and microvascular density in superficial and deep plexuses.",
            "detection_performance": "Studies show FAZ enlargement and reduced macular/foveal vascular density in AD versus controls; quantitative sensitivity/specificity not reported in review; affected by image quality and ocular/ systemic comorbidities.",
            "disease_stage_detected": "May detect microvascular changes prior to clinical symptoms (preclinical / early stages) and in symptomatic AD",
            "study_type": "human imaging studies, systematic reviews/meta-analyses cited",
            "study_population": "Patients with AD and control groups in cited OCT-A studies; sample sizes vary and are not uniformly reported in review.",
            "limitations_or_counterpoints": "Readings influenced by image quality, ocular anatomy, hypertension, diabetes and other eye diseases; values may be altered by race, age, gender; lack of standardization.",
            "uuid": "e6160.14",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Hyperspectral imaging",
            "name_full": "Retinal hyperspectral imaging",
            "brief_description": "Spectral-spatial imaging across many wavelengths that aims to detect spectral signatures of Aβ and other molecular changes in retina non-invasively.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "Hyperspectral retinal imaging",
            "detection_method_description": "Acquires images across contiguous wavelengths to generate a hyperspectral cube, allowing spectral identification of molecular constituents (e.g., Aβ aggregates) in the retina.",
            "detection_performance": "Promising discrimination in AD mouse models and preliminary human studies showing separation of AD pathology vs controls; specific sensitivity/specificity/AUC metrics not provided; larger replication studies required.",
            "disease_stage_detected": "Reported to distinguish AD-pathology positive patients and preclinical animal models (potential for early detection)",
            "study_type": "animal model studies and early human feasibility studies",
            "study_population": "AD mice (e.g., 5xFAD) and small human cohorts in preliminary studies; larger cohorts not yet reported in review.",
            "limitations_or_counterpoints": "Technique is emerging — needs larger replication, standardization; unknown generalizability and specificity vs other retinal pathologies.",
            "uuid": "e6160.15",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Fundus photography",
            "name_full": "Retinal fundus photography",
            "brief_description": "Two-dimensional color imaging of the retina useful for assessing vessel caliber, tortuosity and other microvascular features that may reflect AD-associated vascular changes.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "Fundus photography",
            "detection_method_description": "Captures color images of the posterior pole enabling quantification of vascular geometry (caliber, tortuosity, branching) and detection of microvascular signs linked to cerebral pathology.",
            "detection_performance": "Used to detect narrower venules and more tortuous vessels in AD; review states fundus photography provides detailed images with high sensitivity and specificity for vascular features but does not provide exact diagnostic metrics for AD; best used complementarily.",
            "disease_stage_detected": "Detects vascular changes potentially in preclinical and clinical stages",
            "study_type": "cross-sectional imaging studies and systematic reviews",
            "study_population": "Various human cohorts; study sizes vary and are not consistently reported in review.",
            "limitations_or_counterpoints": "Not a standalone diagnostic tool; vascular changes are non-specific and can be caused by other systemic/ocular diseases; image-based measures are influenced by acquisition and analysis methods.",
            "uuid": "e6160.16",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Vitreous Aβ/pTau",
            "name_full": "Vitreous humor sampling for Aβ and phosphorylated tau",
            "brief_description": "Direct measurement of Aβ and pTau proteins in intraocular vitreous fluid, which correlates with cognitive function but requires invasive intraocular sampling.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "Vitreous humor biomarker analysis",
            "detection_method_description": "Biochemical assays of vitreous fluid quantify Aβ and pTau concentrations which have been correlated with cognitive impairment.",
            "detection_performance": "Reduced Aβ and pTau levels reported and correlated with cognitive function in cited studies; exact sensitivity/specificity not provided; method is invasive (requires intraocular surgery).",
            "disease_stage_detected": "Reported correlations with cognitive impairment and AD pathology; may reflect disease state rather than early screening",
            "study_type": "human intraocular fluid measurement studies",
            "study_population": "Patients undergoing intraocular procedures in which vitreous was sampled; sample sizes limited by surgical contexts (not specified in review).",
            "limitations_or_counterpoints": "Invasiveness makes it impractical as a screening tool; surgical risks and feasibility limit clinical applicability.",
            "uuid": "e6160.17",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Lens fluorescent ligand",
            "name_full": "Fluorescent ligand binding to Aβ in crystalline lens (eye-drop + imaging)",
            "brief_description": "Topical ligand designed to bind ocular Aβ combined with laser scanning detection to visualize Aβ accumulation in the lens non-invasively.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "Fluorescent ligand imaging of lens Aβ",
            "detection_method_description": "Apply a fluorescent ligand as an eye drop that binds Aβ, then use a scanning device to detect ligand fluorescence in the lens, which was correlated with brain measures in preliminary studies.",
            "detection_performance": "Exploratory studies report correlations between lens signal and brain Aβ; specific diagnostic metrics not reported; further validation ongoing.",
            "disease_stage_detected": "Potential for early detection but currently exploratory",
            "study_type": "exploratory human trials and imaging feasibility studies",
            "study_population": "Small exploratory cohorts in early studies; not specified in review.",
            "limitations_or_counterpoints": "Some post-mortem studies failed to find Aβ in lens; technique is exploratory and requires validation; may not represent whole-brain pathology.",
            "uuid": "e6160.18",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "CCM",
            "name_full": "Corneal confocal microscopy (CCM)",
            "brief_description": "Non-invasive high-resolution imaging of corneal nerve fibers (subbasal nerve plexus) proposed to reflect peripheral and central neurodegeneration including AD.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "Corneal confocal microscopy",
            "detection_method_description": "In vivo microscopy that quantifies corneal nerve morphology and density; alterations have been reported in diabetic neuropathy and other neurodegenerative diseases and may correlate with cholinergic deficits in AD.",
            "detection_performance": "Used successfully in peripheral neuropathy and PD/MS studies; for AD, potential signal exists but retinal-specific insight is limited; no AD-specific sensitivity/specificity reported in review.",
            "disease_stage_detected": "May detect peripheral neurodegeneration even in early disease, but AD-specific data are preliminary",
            "study_type": "cross-disease imaging studies, pilot studies",
            "study_population": "Studies in diabetic neuropathy, Parkinson's disease, MS; AD-specific cohorts limited in review.",
            "limitations_or_counterpoints": "CCM assesses corneal (anterior eye) nerves rather than retina; relationship to central AD pathology is indirect and requires further validation.",
            "uuid": "e6160.19",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        },
        {
            "name_short": "Pupillometry",
            "name_full": "Pupillometry / pupillary light reflex testing",
            "brief_description": "Measurement of pupil size and dynamic light responses that may reflect autonomic and cholinergic dysfunction in AD and correlate with memory function.",
            "citation_title": "Potential Retinal Biomarkers in Alzheimer's Disease",
            "mention_or_use": "mention",
            "cause_type": null,
            "cause_description": null,
            "evidence_for_cause": null,
            "evidence_against_cause": null,
            "detection_method": "Pupillometry",
            "detection_method_description": "Quantitative recording of pupillary responses (size, constriction/dilation dynamics) to light stimuli as a non-invasive biomarker of autonomic/cholinergic dysfunction linked to AD.",
            "detection_performance": "Reported changes include increased pupil size and less pronounced pupillary light reflex in AD; pupillometry can distinguish some at-risk individuals but exact diagnostic metrics not provided in review.",
            "disease_stage_detected": "Reported in early risk states and symptomatic AD in some studies",
            "study_type": "human observational studies and biomarker feasibility research",
            "study_population": "Human cohorts in cited studies; sample sizes vary and are not explicitly enumerated in the review.",
            "limitations_or_counterpoints": "Pupillary measures are influenced by many factors (medications, autonomic conditions, lighting); not disease-specific and require standardized protocols.",
            "uuid": "e6160.20",
            "source_info": {
                "paper_title": "Potential Retinal Biomarkers in Alzheimer’s Disease",
                "publication_date_yy_mm": "2023-10"
            }
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "The amyloid cascade hypothesis",
            "rating": 2,
            "sanitized_title": "the_amyloid_cascade_hypothesis"
        },
        {
            "paper_title": "Microglia in Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "microglia_in_alzheimers_disease"
        },
        {
            "paper_title": "Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "retinal_amyloid_pathology_and_proofofconcept_imaging_trial_in_alzheimers_disease"
        },
        {
            "paper_title": "Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease",
            "rating": 2,
            "sanitized_title": "noninvasive_in_vivo_hyperspectral_imaging_of_the_retina_for_potential_biomarker_use_in_alzheimers_disease"
        },
        {
            "paper_title": "Optical coherence tomography in Patients with Alzheimer's Disease: What Can It Tell Us?",
            "rating": 2,
            "sanitized_title": "optical_coherence_tomography_in_patients_with_alzheimers_disease_what_can_it_tell_us"
        },
        {
            "paper_title": "Retinal Vascular Changes in Alzheimer's Dementia and Mild Cognitive Impairment: A Pilot Study Using Ultra-Widefield Imaging",
            "rating": 1,
            "sanitized_title": "retinal_vascular_changes_in_alzheimers_dementia_and_mild_cognitive_impairment_a_pilot_study_using_ultrawidefield_imaging"
        },
        {
            "paper_title": "Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer's disease",
            "rating": 1,
            "sanitized_title": "retinal_ganglion_cell_analysis_using_highdefinition_optical_coherence_tomography_in_patients_with_mild_cognitive_impairment_and_alzheimers_disease"
        },
        {
            "paper_title": "Intranasal insulin as a treatment for Alzheimer's disease: A review of basic research and clinical evidence",
            "rating": 1,
            "sanitized_title": "intranasal_insulin_as_a_treatment_for_alzheimers_disease_a_review_of_basic_research_and_clinical_evidence"
        }
    ],
    "cost": 0.027150499999999998,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><p>Potential Retinal Biomarkers in Alzheimer's Disease
31 October 2023</p>
<p>Anna Atlante 
Daniela Valenti 
Mariana Yolotzin Garc-Bermúdez 0000-0001-8652-5374
Rupali Vohr 0000-0002-8385-7039
Kristine Freude 0000-0001-9480-2386
Peter Van Wijngaard 0000-0002-8800-7834
Keith Martin 0000-0002-9347-3661
Maj Schneider Thomsen 0000-0002-8385-7039
Blanca Irene Aldana 0000-0002-8385-7039
Miriam Kolko miriamk@sund.ku.dk 0000-0001-8697-0734</p>
<p>1 Eye Translational Research Unit, Department of Drug Design and Pharmacology, University of Copenhagen,
2100 Copenhagen, Denmark Rigshospitalet, 2600 Glostrup, Denmark 1870 Frederiksberg, Denmark East Melbourne, VIC 3002, Australia Melbourne, VIC 3010, Australia Cambridge CB2 0QQ, UK 9220 Aalborg, Denmark 2100 Copenhagen, Denmark</p>
<p>2 Department of Ophthalmology, Copenhagen University Hospital,</p>
<p>3 Group of Stem Cell Models and Embryology, Department of Veterinary and Animal Sciences, University of Copenhagen,</p>
<p>4 Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital,</p>
<p>5 Ophthalmology, Department of Surgery, University of Melbourne,</p>
<p>6 Department of Clinical Neurosciences, University of Cambridge,</p>
<p>7 Neurobiology Research and Drug Delivery, Department of Health, Science and Technology, Aalborg University,</p>
<p>8 Neurometabolism Research Group, Department of Drug Design and Pharmacology, University of Copenhagen,</p>
<p>Potential Retinal Biomarkers in Alzheimer's Disease
31 October 20234E916EF2915507552E8981E5BEE1F36C10.3390/ijms242115834Received: 1 September 2023 Revised: 18 October 2023 Accepted: 25 October 2023García-Bermúdez, M.Y.Vohra, R.Freude, K.Wijngaarden, P.v.Martin, K.Thomsen, M.S.Aldana, B.I.Kolko, M. Potential Retinal Biomarkers in Alzheimer's Alzheimer's diseaseretinal alterationsocular biomarkersmitochondriametabolism
Alzheimer's disease (AD) represents a major diagnostic challenge, as early detection is crucial for effective intervention.This review examines the diagnostic challenges facing current AD evaluations and explores the emerging field of retinal alterations as early indicators.Recognizing the potential of the retina as a noninvasive window to the brain, we emphasize the importance of identifying retinal biomarkers in the early stages of AD.However, the examination of AD is not without its challenges, as the similarities shared with other retinal diseases introduce complexity in the search for AD-specific markers.In this review, we address the relevance of using the retina for the early diagnosis of AD and the complex challenges associated with the search for AD-specific retinal biomarkers.We provide a comprehensive overview of the current landscape and highlight avenues for progress in AD diagnosis by retinal examination.</p>
<p>Introduction</p>
<p>Alzheimer's disease (AD) is a neurodegenerative brain disorder and the most common cause of dementia [1,2].Recently, AD has been recognized as a global public health priority by the World Health Organization [3].It is characterized by the presence of extracellular amyloid-β (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs) consisting of hyperphosphorylated tau protein (pTau) [4,5].</p>
<p>The amyloid cascade hypothesis postulates that altered production and clearance of Aβ is the major driving factor for AD pathogenesis in the brain, as abnormal accumulation of Aβ disrupts synaptic function, leading to neuronal loss and the characteristic neurodegeneration [6,7].It is also known that the blood-brain barrier is compromised in AD, allowing the extravasation of fibrinogen and inflammatory mediators that activate microglial cells [8,9].Microglia act as resident phagocytes and mediate synapse pruning by engulfing synapses [10], and once activated, microglia tend to form clusters around Aβ plaques [11], which increases microglial proliferation [12].In addition, microglial exosomes have been shown to propagate pTau [12,13], while the downregulation of microglial homeostatic genes involved in regulation has been reported to correlate with neuronal loss [14].</p>
<p>Activated microglia secrete inflammatory factors [10,15], including reactive oxygen species (ROS) [16].Under normal physiological function, the reactive species generated can be controlled by antioxidant defenses [17].However, in the early stages of AD, oxidative stress is present, and glia and neurons are highly sensitive to this [17], as brain cells respond to oxidative stress, they enter a cycle of increased ROS generation, causing more oxidative stress and mitochondrial damage, ultimately leading to cell death [18,19].</p>
<p>Screening for AD involves several techniques, including cognitive tests, neuroimaging, cerebrospinal fluid (CSF) analysis, blood tests, and genetic testing [20][21][22].Cognitive tests assess memory and cognitive function, while neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) can detect structural and protein changes in the brain [23].CSF analysis and blood tests provide information on biomarkers associated with AD [21,24], and genetic testing can identify mutations in familial forms of the disease [25].However, a definitive diagnosis can only be made at autopsy [26].</p>
<p>There are several difficulties with diagnosing AD.The most important is that early diagnosis remains challenging, as clinical symptoms often appear late in the disease [27].In addition, the overlap of symptoms with other neurodegenerative diseases makes differentiation difficult [20], and biomarkers may lack specificity and be present in individuals without AD [28].Accurate and widespread diagnosis is further complicated by access to specialized testing, ethical issues, and economic concerns.Despite these difficulties, research is underway to improve the accuracy and accessibility of AD detection.It also aims to find new ways to study the disease and detect it in its early stages.</p>
<p>Retinal alterations are one of the earliest signs of AD [29].Several post-mortem studies have shown Aβ plaques and NFTs in the retinas of AD patients [29][30][31].In parallel, the retinal glial cell types, such as microglia and macroglia, become activated and change their morphology and immune phenotype [32].In particular, macroglia, namely Müller glia, and astrocytes, are important for retinal homeostasis [33].Müller glia are the most abundant glial cell type in the retina [34] and require large amounts of energy to maintain their functions, such as ensuring the survival of retinal ganglion cells (RGCs) [19,35,36].Increased levels of oxidative stress have been shown to decrease glutamate transport and to reduce both the glycolytic activity and the mitochondrial respiratory function in Müller glia [37].As changes in glial cells and cellular energetics are implicated in both AD and retinal dysfunction, a growing body of research suggests that energetic instability in the retina may be a predictor of AD.</p>
<p>Refs. [38,39] Certain clinical signs have been observed in AD patients, including increased pupil size [40] and a less pronounced pupillary light reflex [41], and the presence of Aβ 40 in the aqueous humour comparable to levels found in cerebrospinal fluid [42].However, in post-mortem eyes of patients with AD, no deposits of Aβ have been reported in the lens [43].Interestingly, increased cupping of the optic nerve has also been reported in AD [38], whereas a mouse study using Aβ injection found no axonal damage to the optic nerve [44].In addition to anatomical manifestations, visual and motor impairments have also been reported in AD patients.These impairments include abnormal hypometric saccades, reduced visual acuity, impaired contrast sensitivity, stereopsis, lack of hand-eye coordination, impaired fixation of the eye, and difficulty in identifying objects [38,39,45] These changes provide predictive and progression information on neurodegenerative changes and represent potential ocular biomarkers of AD (Figure 1).</p>
<p>The diagnosis of AD is challenging because of the subjectivity of the methods used and the presence of other conditions that present with similar cognitive impairment, such as vascular dementia [46].This results in limited sensitivity and specificity, leading to an inaccurate diagnosis in 10-15% of AD cases [47].In recent years, considerable progress has been made in techniques for detecting AD-related disorders, but many of these are invasive and expensive, so a new approach to detecting AD, such as retinal screening, should be considered.At present, there are non-invasive and low-cost techniques for the detection of retinal and ocular changes that are associated with AD [48].However, the similarity of the pathology to other diseases compels us to continue the study of changes that can be considered as specific retinal and ocular biomarkers in AD.This would also allow us to study AD from a new perspective, as the ocular and retinal changes already observed could be starting in the brain, allowing us to make a timely diagnosis and perhaps stop the progression of AD, giving patients a better quality of life.</p>
<p>Int. J. Mol.Sci.2023, 24, x FOR PEER REVIEW 3 of 26 similarity of the pathology to other diseases compels us to continue the study of changes that can be considered as specific retinal and ocular biomarkers in AD.This would also allow us to study AD from a new perspective, as the ocular and retinal changes already observed could be starting in the brain, allowing us to make a timely diagnosis and perhaps stop the progression of AD, giving patients a better quality of life.In this review, we highlight the compelling parallels between the retinal and cerebral manifestations of AD given their close association.We provide a detailed account of the retinal structure and cell alterations observed in the context of AD.Furthermore, we offer insights into the intricate interplay between retinal cells and the resulting energetic impairment, oxidative stress, and mitochondrial dysfunction.At the same time, we outline the major challenges in retinal AD research caused by shared pathophysiological mechanisms with certain retinal diseases.</p>
<p>Lastly, we discuss the promising diagnostic techniques already available for the detection of retinal and ocular alterations in AD, which offer the dual advantage of early diagnosis and potentially dynamic monitoring of disease progression.This offers an alternative perspective for studying AD through retinal and ocular changes.However, it should be noted that some of these innovative approaches are still in the research phase with encouraging preliminary results.</p>
<p>The Retina: A Window to the Brain</p>
<p>The retina is a part of the central nervous system (CNS), originating from an outpouching of the diencephalon [49].The retina contains a high density of neurons that form a sensory extension of the brain [50].Visual input is converted into neuronal signals in the photoreceptor cells and transmitted to the bipolar cells and then to the RGCs, the output neurons of the retina.RGC axons remain unmyelinated in the retina and converge on the optic nerve, where they become myelinated and travel to the visual centers in the brain.This lack of myelination in the intraretinal portions of RGC axons, which is essential for light to travel unimpeded to the photoreceptors, combined with a semi-hypoxic environment, renders the retina susceptible to metabolic stress [19].</p>
<p>The retina is dependent on a well-regulated process for the maintenance of a proper blood supply for the support of cellular functions [51].Studies have shown changes in the retinal vasculature, the mid-peripheral retina [52], and the foveal avascular zone (FAZ) in AD, including changes in vessel density, thickness, and integrity [53,54].Angiogenesis can In this review, we highlight the compelling parallels between the retinal and cerebral manifestations of AD given their close association.We provide a detailed account of the retinal structure and cell alterations observed in the context of AD.Furthermore, we offer insights into the intricate interplay between retinal cells and the resulting energetic impairment, oxidative stress, and mitochondrial dysfunction.At the same time, we outline the major challenges in retinal AD research caused by shared pathophysiological mechanisms with certain retinal diseases.</p>
<p>Lastly, we discuss the promising diagnostic techniques already available for the detection of retinal and ocular alterations in AD, which offer the dual advantage of early diagnosis and potentially dynamic monitoring of disease progression.This offers an alternative perspective for studying AD through retinal and ocular changes.However, it should be noted that some of these innovative approaches are still in the research phase with encouraging preliminary results.</p>
<p>The Retina: A Window to the Brain</p>
<p>The retina is a part of the central nervous system (CNS), originating from an outpouching of the diencephalon [49].The retina contains a high density of neurons that form a sensory extension of the brain [50].Visual input is converted into neuronal signals in the photoreceptor cells and transmitted to the bipolar cells and then to the RGCs, the output neurons of the retina.RGC axons remain unmyelinated in the retina and converge on the optic nerve, where they become myelinated and travel to the visual centers in the brain.This lack of myelination in the intraretinal portions of RGC axons, which is essential for light to travel unimpeded to the photoreceptors, combined with a semi-hypoxic environment, renders the retina susceptible to metabolic stress [19].</p>
<p>The retina is dependent on a well-regulated process for the maintenance of a proper blood supply for the support of cellular functions [51].Studies have shown changes in the retinal vasculature, the mid-peripheral retina [52], and the foveal avascular zone (FAZ) in AD, including changes in vessel density, thickness, and integrity [53,54].Angiogenesis can be studied in a non-invasive way and since it is associated with AD [55], it is considered a possible diagnostic biomarker, but it requires further standardization.</p>
<p>Outer Retinal Changes in AD Patients</p>
<p>The outer retina, the outermost layer of cells in the retina, consists of photoreceptor cells and the retinal pigment epithelium (RPE) [56,57], which has received increasing attention in AD.However, compared to the inner retina, its role in AD is less well understood.The photoreceptor cells, which are essential for the capture of light and the initiation of the visual process, have shown signs of progressive degeneration in AD mice [58], potentially contributing to the visual impairment associated with the disease.</p>
<p>Optical coherence tomography (OCT) studies have correlated volumetric changes in the outer retina, ellipsoid zone to the retinal pigmented epithelium, with changes in brain volume in patients with AD, reflecting photoreceptor outer segment shortening [59].Photoreceptor dysfunction accompanied by Aβ deposition is a common observation in animal models of AD [60,61].In addition, a clinical study including 39 patients with mild AD and 21 patients with moderate AD showed impaired color perception in addition to photoreceptor degeneration compared to controls by OCT [62].</p>
<p>Visual impairment, including problems with contrast sensitivity, color discrimination, and depth perception, is a recognized symptom of AD [38,45].Although the exact mechanisms remain unclear, these visual problems suggest a link between AD and the outer retina.Further research is needed to establish a definitive link and to better understand the role of the outer retina in AD.</p>
<p>Inner Retinal Alterations</p>
<p>The inner retina, which extends from the inner limiting membrane to the outer plexiform layer, consists of RGCs, the nerve fiber layer, and bipolar cells [63].The RGCs are responsible for the transmission of visual information from the retina to the brain and show signs of degeneration in people with AD [38].The thinning of the nerve fiber layer (NFL) and ganglion cell layer (GCL) in people with AD has been demonstrated using advanced imaging techniques such as OCT [38,64,65], suggesting structural changes in the inner retina.</p>
<p>In addition, post-mortem examinations of the retinas of patients with AD show the presence of Aβ in the NFL and GCL [31,66].The presence of Aβ deposits, Aβ40 and Aβ42 alloforms, vascularization, and inflammation have been reported in the retinas of AD patients and mice [30,[66][67][68].</p>
<p>Furthermore, pTau accumulation has been found in the inner plexiform layer and in the GCL where it has been linked to RGCs loss and inflammation [29,38,69].Several post-mortem studies have reported an increase in pTau in the peripheral retina of people with AD [70].This information highlights the link between AD-related changes in the brain and manifestations in the retina.</p>
<p>Microglia Abnormalities</p>
<p>Microglia are the resident immune cells of the CNS, including the brain and retina, where they are involved in the maintenance of homeostasis [71,72].Microglia play a vital role in brain plasticity and development [73] through the removal of synapses from neuronal cell bodies [74,75].Furthermore, microglia are important contributors to proper synaptic processing in health but are also involved in pathological conditions by disrupting neuronal connections [76].Although astrocytes and microglia do not yet appear to play a direct role in synapse degeneration, neurons appear to be more active in this process [77].</p>
<p>Under normal circumstances, both the Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) and Apolipoprotein E (ApoE) are involved in microglial cells in the phagocytosis of apoptotic neurons in the brain [78].However, mutations in TREM2 are associated with an increased risk of late-onset AD as Aβ is not cleared properly, resulting in increased accumulation [10,79].Increased levels of pro-inflammatory mediators such as interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α) have been found in the cerebrospinal fluid, contributing to neuroinflammation in AD [12,80].Aβ activation of microglia requires the participation of the receptor complex CD36, α6β1 integrin, and CD47, which are involved in the internalization of Aβ [81], and receptors such as CD14 and Toll-like receptors 2 and 4 (TLR-2 and TLR-4) [82][83][84].</p>
<p>Under physiological conditions, microglia are found in the inner retina.As in the brain, they can be activated to remove debris and pathogens in response to injury or infection [71].And in AD, activated microglia can infiltrate the outer retina [72].</p>
<p>Macroglia: The Importance of Müller Glia in AD</p>
<p>In addition to their homeostatic and metabolic support functions, Müller glia is also involved in the regulation of synaptic activity in the inner retina [15,85].Müller glia are also sensitive to microglial changes [86] and can be activated in neurodegenerative diseases such as AD.Müller glia prevents the accumulation of glutamate in the synaptic clefts via excitatory amino acid transporters 1 and 2 (EAAT1 and EAAT2, also known as GLT-1), thereby preventing excitotoxicity [87].Müller glia requires substantial bioenergetic support, provided primarily by a large number of mitochondria, to perform glutamate uptake and maintain retinal homeostasis [88].</p>
<p>The retina is one of the highest lactate-containing organs in the human body relative to size, and lactate has been shown to act as an energy substrate for retinal cells [34,[89][90][91].Müller glia and RGCs are the main cells responsible for lactate production in the retina [89].</p>
<p>Studies have shown increased cell survival in both cultures of isolated primary RGCs and Müller glia from neonatal mice (C57BL/6J) retinas when exposed to L-lactate.In addition to acting as an energy substrate, lactate also activates the G-coupled protein receptor 81 (GPR81) [34].Lactate has been shown to have regulatory functions in the retina, such as increasing glutamate uptake, improving mitochondrial function and increasing glucose consumption, protecting against neuroinflammation, and providing neuroprotection in neurodegenerative conditions [89].</p>
<p>The bidirectional interaction between microglia and Müller glia is thought to act as a regulator in neuron-microglia interaction.Müller glia can detect neurotransmitter signals from neuronal and synaptic activity [86,87,92].Adenosine triphosphate (ATP) is also known as a chemotactic agent [93], and Müller glia, via ATP secretion, can mediate activity dependent regulation of microglial dynamics [87,89], as well as regulate retinal blood flow [94].The release of ATP from Müller glia through pannexin channels drives a resting state in microglia [95] (Figure 2).</p>
<p>Intricate Connection Means the Retina Mirrors the Brain</p>
<p>Findings from in vivo and in vitro studies in humans and animal models show the similarities in the manifestations of AD in the brain and retina.Post-mortem studies of the retina in humans and some animal models of AD have shown activation of microglia and Müller glia, as well as disturbances in energetic, metabolic, and mitochondrial processes.This suggests that Aβ accumulation triggers neurodegeneration in the retina similar to that observed in the brain [35,96] (Table 1).</p>
<p>Findings</p>
<p>In Vitro In Vivo Reference</p>
<p>Intricate Connection Means the Retina Mirrors the Brain</p>
<p>Findings from in vivo and in vitro studies in humans and animal models show the similarities in the manifestations of AD in the brain and retina.Post-mortem studies of the retina in humans and some animal models of AD have shown activation of microglia and Müller glia, as well as disturbances in energetic, metabolic, and mitochondrial processes.This suggests that Aβ accumulation triggers neurodegeneration in the retina similar to that observed in the brain [35,96] (Table 1).Aβ accumulation in the brain has been found decades before the onset of symptoms [136,137], and several reports indicate that retinal Aβ follows a similar time course to that in the brain [67,138].Retinal abnormalities have also been associated with AD progression and cognitive decline.These include loss of RGCs [120], reduced thickness of the retinal NFL (RNFL) and RGC layer and reduced retinal blood flow [102,121,139], as well as decreased thickness in the macular area as a result of inner layer degeneration [62].Taken together, this suggests that the eye can be considered a window to study AD.</p>
<p>Energetic Impairment</p>
<p>The brain has a remarkably high energy requirement, with glucose being the main energy substrate [104].However, lactate, ketone bodies, glycogen, and amino acids can also be used as bioenergetic substrates under certain circumstances [118].Pathogenic factors such as abnormalities in glucose transport, impaired glucose metabolism, and mitochondrial dysfunction in the brain occur in AD and have been characterized in animal models [108,118,140] (Figure 3).</p>
<p>Energetic Impairment</p>
<p>The brain has a remarkably high energy requirement, with glucose being the main energy substrate [104].However, lactate, ketone bodies, glycogen, and amino acids can also be used as bioenergetic substrates under certain circumstances [118].Pathogenic factors such as abnormalities in glucose transport, impaired glucose metabolism, and mitochondrial dysfunction in the brain occur in AD and have been characterized in animal models [108,118,140] (Figure 3).Like the brain, the retina is one of the most energy-demanding tissues in the body.To meet its vast energy demands [141], the retina is rich in mitochondria, particularly in the RPE, photoreceptors, and Müller glia, as well as in the RGC axons at the optic nerve head [102,142].To achieve this, the structure and shape of the mitochondria are maintained by a balance of mitochondrial fission and fusion.Fission is the mitochondrial fragmentation that occurs when dynamin-related protein 1 (Drp1) and mitochondrial fission 1 protein (Fis1) are recruited to the outer mitochondrial membrane, resulting in smaller and more functional mitochondria [143].Fusion allows mitochondria to support each other, compensating for defects in damaged mitochondria by physically fusing the outer and inner membranes of two different mitochondria [144].This process also protects mitochondria from harmful DNA mutations and allows them to change shape for specific functions.The lack of mitochondrial fusion can therefore increase ROS production and decrease ATP synthesis [145].Reports have suggested that alterations in these mitochondrial dynamics may be involved in neurodegenerative diseases.In AD, impaired fission-fusion dynamics can lead to mitochondrial dysfunction in the brain [146][147][148], with reduced levels of Drp1 and increased levels of Fis1 reported [149].</p>
<p>Deposition of Aβ has been shown to affect mitochondrial function.For instance, even mild increases in Aβ have been found to have detrimental effects on mitochondria [150].In addition, several studies have indicated that mitochondrial morphology and function can be affected by inhibition of protein import [151], by the interaction of Aβ with the cyclophilin D-dependent mitochondrial permeability transition pore (mPTP) [152,153], and by its binding to mitochondrial Aβ-binding alcohol dehydrogenase (ABAD) [150,154].Recent studies have also demonstrated that metabolic alterations in the retina of an AD mouse model, including decreased glutamine synthesis and glucose hypometabolism, provide insight into potential neuroprotective pathways [19].</p>
<p>Oxidative Stress and Mitochondrial Dysfunction</p>
<p>Oxidative stress and impaired Ca 2+ homeostasis contribute to the pathogenesis and progression of AD [119,155].Upregulation of oxidative phosphorylation (OXPHOS) activity can lead to an increase in ROS that directly affects neurons [6] and glia [112] in the AD brain.</p>
<p>Neurons are fundamentally dependent on mitochondrial OXPHOS to meet their energy needs.When neurons are damaged, they respond by upregulating OXPHOS, better known as the inverse Warburg effect [6].It shifts from a healthy state to pathological aging with subsequent amyloid plaque accumulation, DNA damage, increased ROS production, and neuronal loss due to their high susceptibility to free radicals [113].The inverse Warburg effect suggests that an imbalance between the fusion and fission of intact and damaged mitochondria may play an important role in the pathogenesis of AD [6,156].In AD brain neurons, altered Ca 2+ influx in dysfunctional mitochondria can lead to altered regulation of neurotransmitters, neurogenesis, neuronal plasticity, and lipid synthesis [157].It has also been suggested that Aβ enters the mitochondria and interacts with mitochondrial proteins that produce ROS and free radicals [145].</p>
<p>Research has shown that at least 42 metabolic proteins, including glyceraldehyde-3-phosphate dehydrogenase (GAPDH), are downregulated in the AD brain.GAPDH is involved in glucose metabolism and has been shown to interact with amyloid precursor protein (APP).The non-glycolytic activity of GAPDH can be modulated by ROS and GAPDH activity is reduced in the AD brain, which may contribute to the loss of neuronal function and subsequent neurodegeneration [158,159].</p>
<p>It has been suggested that metabolic pathways become dysregulated with age, leading to mitochondrial dysfunction and reduced ATP production [160].Mitochondrial changes in AD have also been shown to correlate with reduced energy metabolism and oxidative stress [150].In this context, it is proposed that damaged neurons in an AD brain attempt to protect themselves and compensate for energy deprivation by switching to glycolysis with lactate and pyruvate to promote rapid ATP production.Residual lactate and pyruvate enter the mitochondria and the tricarboxylic acid (TCA) cycle for OXPHOS [161].Competition for lactate also occurs between neurons, and neurons with upregulated OXPHOS outperform the rest.They have the advantage of using lactate from astrocytic glycolysis as an energy substrate, thus sparing glucose for healthy neurons [160,162].In addition, a defect in cytochrome c oxidase has been implicated in the bioenergetic deficit of AD [127] as a result of mitochondrial DNA (mtDNA) mutations [163].In aged animals, reduced glutathione levels have been associated with mitochondrial damage [87,105].</p>
<p>Similar to the brain, the chronic increase of ROS in the AD retina contributes to oxidative stress, mitochondrial dysfunction, and cell death [126,128] (Figure 4).This excessive ROS production is thought to be related to abnormal stimulation of NMDAR by Aβ oligomers [134] and mitochondrial dysfunction.Aβ aggregates bind redox-active metals such as iron and copper, sources of ROS, causing mitochondrial damage and subsequent neurotoxicity [122].Aβ deposits and NFTs activate retinal astrocytes and microglia [164] with the production of inflammatory cytokines such as IL-1β, IL-6, and TNF-α [165], which together with ROS may cause neurotoxicity.RGCs appear to be particularly susceptible to this neurotoxic effect and thinning of the retinal nerve fiber layer is an increasingly recognized phenomenon in AD [122].</p>
<p>Studies of the retina in mouse models of AD suggest that Aβ peptides are responsible for increased Ca 2+ in mitochondria, leading to mitochondrial fragmentation, disruption of the fission-fusion balance, and mitochondrial dysfunction [102].</p>
<p>It is still unknown whether mitochondria play a primary or secondary role in the pathogenesis of AD, as it is debated as to whether this is a consequence of amyloid deposition, or whether it is directly involved in the early stages of AD.Therefore, an alternative hypothesis is that amyloid/tau pathology and mitochondrial dysfunction are correlated [166].</p>
<p>gomers [134] and mitochondrial dysfunction.Aβ aggregates bind redox-active metals such as iron and copper, sources of ROS, causing mitochondrial damage and subsequent neurotoxicity [122].Aβ deposits and NFTs activate retinal astrocytes and microglia [164] with the production of inflammatory cytokines such as IL-1β, IL-6, and TNF-α [165], which together with ROS may cause neurotoxicity.RGCs appear to be particularly susceptible to this neurotoxic effect and thinning of the retinal nerve fiber layer is an increasingly recognized phenomenon in AD [122].Healthy and dysfunctional mitochondria in the retina.The RPE/photoreceptor complex resides in a highly oxidative environment.A large number of mitochondria are located in the outer end of Müller glia, in the inner segments of photoreceptors, and in the basal part of RPE cells.The retina is a highly energy demanding organ.In healthy retinal cells, glycolysis occurs in the cytoplasm, providing pyruvate and lactate to the mitochondria where they can be substrates for acetyl-CoA synthesis, fueling the TCA cycle and electron transport chain (complex I-V) activity with final energy production in the form of ATP.In the Alzheimer's disease retina, glycolysis is affected by the amyloid-β (Aβ) peptide causing the increase in reactive oxidative species (ROS), while Healthy and dysfunctional mitochondria in the retina.The RPE/photoreceptor complex resides in a highly oxidative environment.A large number of mitochondria are located in the outer end of Müller glia, in the inner segments of photoreceptors, and in the basal part of RPE cells.The retina is a highly energy demanding organ.In healthy retinal cells, glycolysis occurs in the cytoplasm, providing pyruvate and lactate to the mitochondria where they can be substrates for acetyl-CoA synthesis, fueling the TCA cycle and electron transport chain (complex I-V) activity with final energy production in the form of ATP.In the Alzheimer's disease retina, glycolysis is affected by the amyloidβ (Aβ) peptide causing the increase in reactive oxidative species (ROS), while hyperphosphorylated tau (pTau) inhibits the electron transport chain, provoking the increase of ROS inside the matrix of the mitochondria.In a harmful cycle, the increase in ROS causes mutations in mitochondrial DNA that will produce defective proteins which in turn decreases ATP and increases ROS with the subsequent oxidative stress, mitochondrial damage</p>
<p>Similarities between Retinal Manifestations in Retinas from AD Patients and Retinal Manifestations in Other Eye Diseases</p>
<p>Studies of retinal diseases are therefore crucial in recognizing the potential of the retina as a window to the brain, providing new insights into neurodegenerative processes.</p>
<p>Common mechanisms and biomarkers of neuronal dysfunction can likely be identified by studying degeneration patterns, proteins, metabolic and energy pathways, and inflammatory responses in different retinal diseases.This approach will not only aid in the early diagnosis of AD but may also potentially improve the understanding of disease progression and the effects of therapeutic interventions (Table 2).Possible [170] Yes [171] Yes [172] Tau protein</p>
<p>Yes [169] Possible [173] Possible [174] No Inflammatory pathways</p>
<p>Yes [18] Yes [175] Yes [18] Yes [176]</p>
<p>Vascular dysfunction</p>
<p>Yes [63] Yes [177] Yes [178] Possible [179] Oxidative stress</p>
<p>Yes [155] Yes [180] Yes [181] Yes [182] Neuroinflammation</p>
<p>Yes [63] Yes [183] Yes [122] Yes [122]</p>
<p>VEGF</p>
<p>No findings Yes [184] Yes [178] Yes [185] Treatment Symptomatic care, no cure, acetylcholinesterase (AChE) inhibitors, memantine, Lecanemab, and Aducanumab Strict blood sugar control, laser therapy, anti-VEGF therapy, surgery Medications, surgery Anti-VEGF therapy, supplements</p>
<p>Diabetic Retinopathy and AD</p>
<p>Diabetic retinopathy (DR) is a leading cause of vision loss and is expected to affect more than 190 million people by 2030 [186].The increasing prevalence of DR is linked to the rise in cases of diabetes associated with the increasing prevalence of obesity and sedentary lifestyles [187].Altered metabolic parameters and modifiable risk factors predisposing to type 2 diabetes mellitus (T2DM) have been associated with the risk of AD [128,[188][189][190][191][192][193].Similarly, both diabetes and diabetic retinopathy are associated with an increased risk of developing AD [194][195][196] and cognitive impairment [197][198][199][200].</p>
<p>Disruption of insulin signaling and abnormal activation of components of the insulin signaling pathway in the brain, features typical of diabetes, have been reported in AD [128,[201][202][203].The brain has a high density of insulin receptors [204,205], and some studies show that Aβ oligomers are involved in removing insulin receptors (IRs), thereby reducing the IR protein tyrosine kinase activity through TNF-α/c-Jun NH 2 -terminal kinase (JNK) activation [128,206].In addition, the retina is also an insulin-sensitive tissue, and it has also been suggested that Müller cells may secrete insulin [207] and that a deficiency in receptor signaling may contribute to retinal cell death [208].</p>
<p>Intranasal insulin has been shown to improve memory in healthy adults, verbal memory in patients with memory impairment, and cognitive performance in patients with early AD and mild cognitive impairment [209][210][211].Insulin has been shown to block the downregulation of IR, IR substrate-1pSer (IRS-1pSer), and oxidative stress, and to protect neurons against synapse loss induced by Aβ oligomers [128,212].GLP-1R agonists activate insulin signaling pathways through G-protein-dependent signaling.This influences the regulation of glucose metabolism and impairs neurological and cognitive function [213,214].In GLP-1R agonist-treated mice, reduction of Aβ plaques and microglial activation have been observed, thereby conferring neuroprotection [213].</p>
<p>Glaucoma and AD</p>
<p>Glaucoma is a progressive optic neuropathy, characterized by RGC loss and progressive visual field loss.It is one of the leading causes of blindness worldwide [33,215,216].As is the case in AD, mitochondrial dysfunction, altered OXPHOS, and increased ROS have been reported to play a role in the pathogenesis of glaucoma [217,218].In addition, similari-ties between AD and glaucoma have long been recognized, as the retinal neurodegeneration in AD appears to predominantly affect RGCs [139].</p>
<p>There is evidence that primary open-angle glaucoma (POAG) and AD may share genetic risk factors.For example, the optineurin (OPTN) gene encodes for the optineurin protein [219], which is expressed in the brain, retina, heart, placenta, kidney, and other tissues [220].Overexpression of OPTN is strongly associated with TNF-α induced death of rat RGC-5 cells [221], suggesting an upregulation in AD [222].Optineurin neurotoxicity may be a common risk factor in normal tension glaucoma (NTG) and AD [220].</p>
<p>Despite these pathogenic similarities, the association between AD and primary POAG remains controversial [219,223,224].Some studies have found no association between POAG and AD [225,226], including a meta-analysis in 2021 that found no association between glaucoma and AD (risk ratio (RR): 1.03, 95% confidence interval (CI): 0.93-1.05;I 2 = 83%, p= 0.55) [227].On the other hand, some studies suggest an association between the two diseases [228,229], including a systematic review and meta-analysis in 2019 that showed an increased risk of AD in glaucoma patients (RR = 1.52; 95% CI: 1.41-1.63;I 2 = 97%, p &lt; 0.001) and an Asian study that found a significant association (RR = 2.03; 95% CI: 1.02-4.07)[230].In addition, studies in Taiwan, Korea, and Canada have all shown that patients with POAG have a higher risk of developing AD [231][232][233], suggesting that POAG may be a predictor of AD in certain demographic groups.The contradictory evidence of associations between AD and glaucoma may be due to the diagnostic criteria used in each study, including diagnostic misclassification.In addition, the fact that some studies may have included only patients with severe dementia, the small size of the cohort in some studies, the inclusion of case-control studies, which may lead to a positive patient selection bias, and the different mean ages of the study participants may also explain the inconsistent conclusions.Future longitudinal studies are needed to better understand the associations between AD and glaucoma.</p>
<p>Age-Related Macular Degeneration and AD</p>
<p>Age-related macular degeneration (AMD) is another major cause of blindness in people over the age of 50 years [234].AMD is a chronic degenerative disease of the macula that affects central vision, and it is characterized by the accumulation of drusen between the RPE and Bruch's membrane [235].</p>
<p>Extracellular deposits of Aβ [236], iron accumulation [237], chronic inflammation, and oxidative stress [122] are common features in the retina of patients with AMD.This suggests a strong correlation and probably overlap in pathology between AD and AMD [15,122,238,239].Li-Yen Wen et al. have shown a 1.23-fold increased risk in AD patients with AMD [240].</p>
<p>Based on the overlapping features of the diseases, iron chelating agents have been proposed as a potential strategy for the treatment of both AD and AMD [122,241,242], together with therapeutic elimination of Aβ accumulation with anti-Aβ antibodies or reduction of Aβ production with β-secretase inhibitors based on the overlapping mechanisms [138].Trials of these therapeutic approaches are currently ongoing.</p>
<p>Overall, as mentioned above, some studies have shown an association between AMD and the risk of AD.However, a UK study of 2088 individuals aged 69 to 97 found a lack of a significant association between AD and early AMD, although AD and AMD have similar pathologies, ApoE status, and vascular risk factors.However, they also mention that although the study was large, only 145 of the 707 participants with dementia were considered to have AMD.Also, some of the people with AMD and AD may have died before the study was conducted.In addition, only one eye was examined in the retinal photography study.Finally, the study was a cross-sectional study which meant that it was impossible to know when the cognitive decline occurred in AMD [243].</p>
<p>Non-Invasive Retinal Imaging to Detect Features of AD</p>
<p>Optical Coherence Tomography (OCT)</p>
<p>The detection of Aβ and tau accumulation in the brain currently relies on the use of PET imaging or CSF analysis, both of which are expensive and invasive [244].Assuming that AD can be predicted via the retina, it is relevant to explore methods for mapping retinal biomarkers [59].In this context, OCT is a non-invasive technique that uses low-coherence interferometry to obtain cross-sectional three-dimensional images of the retina, allowing for the study of retinal thinning, macular thinning, and vascular changes [244].</p>
<p>The thickness of the macula as examined by OCT is a valuable indicator of AD.Studies have shown reduced macular volume and thickness in asymptomatic individuals with a high genetic risk of developing AD [245] and reduced central macular thickness in patients with AD compared to healthy controls [246].</p>
<p>In patients with AD, macular and peripapillary RNFL thinning has been reported in numerous studies using OCT [123,247], suggesting that OCT may be used to detect biomarkers for AD [122,239,[248][249][250][251].At present, these changes lack specificity for disease detection, as there is considerable overlap between OCT findings in AD and several other neurodegenerative diseases, including glaucoma.It should be noted, however, that some factors may affect the OCT measurements, such as elevated intraocular pressure, variable axial length, refractive error, systemic comorbidities, or other eye diseases due to similarities in the pathology [252].</p>
<p>Nevertheless, the use of OCT is a useful tool in the diagnosis and monitoring of retinal diseases and may therefore be a valuable resource in the diagnosis of neurodegenerative diseases, such as AD [123,[253][254][255][256] (Figure 5).Nevertheless, the use of OCT is a useful tool in the diagnosis and monitoring of retinal diseases and may therefore be a valuable resource in the diagnosis of neurodegenerative diseases, such as AD [123,[253][254][255][256] (Figure 5).</p>
<p>Optical Coherence Tomography Angiography (OCT-A)</p>
<p>Vascular changes in the brain, including cerebral amyloid angiopathy and bloodbrain barrier dysfunction, are known to be associated with AD [257].Similarly, AD has also been associated with vascular changes in the retina [252].OCT-A provides a detailed non-invasive examination of the retinal vasculature without the use of contrast agents [258].Studies have shown retinal microvascular network changes, with an enlargement of the FAZ, microvascular density lesions in the deep retinal capillary plexuses, and lower vascular density in whole macular, foveal, and parafoveal zones in people with AD compared to controls [259,260].</p>
<p>Thus, OCT-A may help us detect these changes in the retinal microvasculature before the clinical symptoms of AD appear, which may aid in predicting and evaluating the pro-</p>
<p>Optical Coherence Tomography Angiography (OCT-A)</p>
<p>Vascular changes in the brain, including cerebral amyloid angiopathy and blood-brain barrier dysfunction, are known to be associated with AD [257].Similarly, AD has also been associated with vascular changes in the retina [252].OCT-A provides a detailed non-invasive examination of the retinal vasculature without the use of contrast agents [258].Studies have shown retinal microvascular network changes, with an enlargement of the FAZ, microvascular density lesions in the deep retinal capillary plexuses, and lower vascular density in whole macular, foveal, and parafoveal zones in people with AD compared to controls [259,260].</p>
<p>Thus, OCT-A may help us detect these changes in the retinal microvasculature before the clinical symptoms of AD appear, which may aid in predicting and evaluating the progression of the disease.</p>
<p>Errors in data acquisition or image quality, as well as ocular anatomy and diseases such as hypertension or diabetes, can affect OCT-A readings [261,262].As with OCT, other eye diseases can also affect the readings [262].Furthermore, it must be considered that OCT and OCT-A values may be altered by race, age, or gender [263].</p>
<p>Hyperspectral Imaging</p>
<p>The presence of Aβ deposits in the inner retinal layers of patients with AD has been reported in several studies [264,265].Hyperspectral imaging is an imaging technique that acquires a series of images across many contiguous wavelengths of light to combine spectral and spatial information into a single data cube [266].This emerging imaging technique has shown promise in distinguishing AD mice from wild-type mice [264,267,268].Furthermore, recent studies have shown that hyperspectral imaging may be able to discriminate patients with AD pathology from healthy controls [264,265].Larger replication studies are needed before it is clear whether this imaging technique has clinical value in AD.</p>
<p>Fundus Photography</p>
<p>Fundus photography is a non-invasive imaging technique that produces two-dimensional color images of the back of the eye, including the retina.This provides detailed images with high sensitivity and specificity.These include vessel caliber, tortuosity, and the global geometric branching network [269].The microvascular changes in the retinas of patients with AD include narrower retinal venules and more tortuous retinal vessels, which may reflect changes in vascular structure and function that are associated with the brain pathology of AD and dementia [270][271][272].</p>
<p>Although not a standalone diagnostic tool, fundus photography contributes to our understanding of retinal changes in AD and may complement other diagnostic and followup approaches in AD.</p>
<p>Other Approaches to Detect Biomarkers of AD in the Eye</p>
<p>Aβ and pTau in the Vitreous Humor</p>
<p>Reduced levels of Aβ and pTau have been reported in the vitreous humor and correlated with poor cognitive function.Therefore, whilst it may be technically feasible to use the presence of these proteins as a biomarker for AD [273,274], the method's applicability is limited as it requires surgery to collect intraocular fluid.</p>
<p>Fluorescent Signal of Ligand Bound to Aβ in the Lens</p>
<p>A combination of a fluorescent ligand with an affinity for Aβ and a laser scanning device have been proposed as a means to detect the accumulation of Aβ in the crystalline lens of the eye following application as an eyedrop [275,276], with significant correlations between eye and brain measurements [277].Further studies of this imaging method are in progress for the detection of AD.</p>
<p>Corneal Confocal Microscopy (CCM)</p>
<p>Corneal confocal microscopy (CCM) is a non-invasive ophthalmic imaging technique that has shown promise in the detection of neuronal loss in neurodegenerative diseases.It can detect changes in corneal neurons and is useful in detecting neuropathies such as diabetic neuropathy [278] and can also identify corneal nerve changes in Parkinson's disease [279] and multiple sclerosis [280].The neurotransmitter acetylcholine (ACh) has been shown to play an important role in maintaining the corneal epithelium.Furthermore, ACh is deficient in AD, so changes in corneal structure could be used for the detection and mon-itoring of AD.Therefore, by analyzing the micromorphology of the corneal subbasal nerve plexus (SNP), CCM may provide insight into peripheral and central neurodegeneration in AD [281].</p>
<p>Ocular Manifestations</p>
<p>Anatomic changes in AD extend beyond the retinal layers to include changes in the size of the pupil and optic nerve.Pupillary abnormalities have been observed in individuals with AD, often manifesting as varying responses of the pupil to constrict and dilate in response to light stimulation [282].This may be indicative of underlying neurological dysfunction, as the pupillary reflex is influenced by the sympathetic (adrenergic) and parasympathetic (cholinergic) autonomic nervous systems [283], memory function [284], and brain control of the pupillary muscles [283].To detect these changes in the pupil, pupillometry provides a non-invasive method and a potential biomarker for AD [285].</p>
<p>Another important site of anatomical change in AD is the optic nerve, which connects the eye to the brain.Although not directly observable with routine retinal imaging, there is evidence of retinal ganglion cell degeneration and a widespread axonal degeneration in the optic nerve [286], nerve fiber damage, increased cup-to-disc ratio [287], and with the use of a retinograph, detection of papillary paleness in the optic disk in AD [288].These changes may be the result of axonal and neuronal degeneration in the optic nerve head [39].</p>
<p>Conclusions</p>
<p>AD is a neurodegenerative disorder characterized by the abnormal accumulation of Aβ peptides and tau protein in the brain.Several studies have shown that AD patients have abnormal accumulations of both Aβ and tau in the RGC layer and the inner retina, suggesting a possible link between retinal pathology and AD.Accumulating research suggests that these pathological changes occur in the retina over a similar timeframe as in the brain, making the retina an attractive approach to AD diagnosis.</p>
<p>In AD, mitochondrial dysfunction disrupts energy metabolism, leading to impaired cellular function and an increased susceptibility to neurodegeneration.This impairment extends to retinal cells and may contribute to the retinal degeneration seen in AD.Another consequence of mitochondrial dysfunction is an increase in the production of ROS.The accumulation of ROS in the retina can lead to oxidative stress and further exacerbate retinal degeneration.Taken together, retinal Aβ and tau accumulation, along with reduced mitochondrial function, impaired energy metabolism, and increased ROS production, are likely to contribute to retinal degeneration in AD.</p>
<p>Retinal tests, such as OCT and hyperspectral imaging, offer several advantages in detecting AD compared to traditional clinical brain diagnostic methods.Retinal assays are non-invasive, low-cost, time-efficient, and well-tolerated by patients, making them accessible tools for early detection and disease monitoring.They can detect subtle retinal changes, even before the onset of cognitive symptoms in AD.</p>
<p>It is important to note that there are differences between retinal imaging techniques, such as OCT or OCT-A, which provide more detailed information on retinal structure, thickness, and microvascular changes compared to traditional fundus photography or hyperspectral imaging.However, the combination of some techniques, such as hyperspectral imaging and OCT, may lead to a better and faster diagnosis of AD [289].Other ocular methods, such as CCM, provide insight into the corneal nerve morphology related to AD but do not offer insight into the retina.On the other hand, detection of Aβ by fluorescent signaling in the lens may not provide a complete picture of AD-related changes, and detection of Aβ and pTau in the vitreous humor is an invasive tool requiring surgery.</p>
<p>There are many factors to consider when comparing the cost of retinal techniques for the detection of AD.Methods such as fundus photography are in general more affordable, which makes them more accessible for routine screening.The integration of artificial intelligence (AI) algorithms into these techniques may increase their cost but bring significant benefits such as accuracy and precision.AI can analyze retinal data more comprehensively, potentially leading to the detection of subtle changes associated with early AD.As a result, early detection of AD, early intervention, and increased treatment efficacy would justify this investment.</p>
<p>While retinal and ocular tests are promising, at present they are not standalone diagnostic tools but rather complements to existing clinical techniques.Integration of retinal evaluation with MRI, PET, and other biomarker-based diagnostic approaches may improve the sensitivity and specificity of AD detection, providing a diagnostic strategy that incorporates both brain and retinal pathology.</p>
<p>An understanding of the mechanisms in Alzheimer's retinas could provide valuable insights into the pathophysiology of AD and potentially facilitate the development of novel approaches for early diagnosis and therapeutic strategies for the disease.The U.S. Food and Drug Administration recently approved two anti-amyloid antibodies (Lecanemab and Aducanumab) as disease-modifying therapies for AD.With this treatment, it stands to reason that the implementation of retinal screening for early diagnosis could serve to initiate treatment at a stage when the damage has not yet caused cognitive impairment in the brain, thus providing neuroprotection.</p>
<p>In summary, there is compelling evidence to support retinal changes as biomarkers for the diagnosis and potential prediction of AD.However, there is a lack of consensus on how to implement such a strategy in clinical practice and further research is needed to improve the understanding of the relationship between retinal manifestations and AD.</p>
<p>Figure 1 .
1
Figure 1.Visual changes in Alzheimer's disease and erase AD.Several clinical and functional alterations have been reported in Alzheimer's disease patients, such as decreased pupillary light reflex, increased pupil size, and increased excavation of the optic nerve.Other features include decreased contrast sensitivity, decreased visual acuity, stereopsis, abnormal hypometric saccade, and reduced visual sensitivity, among other alterations.</p>
<p>Figure 1 .
1
Figure 1.Visual changes in Alzheimer's disease and erase AD.Several clinical and functional alterations have been reported in Alzheimer's disease patients, such as decreased pupillary light reflex, increased pupil size, and increased excavation of the optic nerve.Other features include decreased contrast sensitivity, decreased visual acuity, stereopsis, abnormal hypometric saccade, and reduced visual sensitivity, among other alterations.</p>
<p>Int. J. Mol.Sci.2023, 24, x FOR PEER REVIEW 6 of 26</p>
<p>Figure 2 .
2
Figure 2. Interaction between Müller glia and microglia.Signals from Müller glia induce changes in microglia, causing them to either rest or become activated: (1) Activated microglia: Once activated, Müller glia activate microglia by CCL2 and CCL3 secretion.(2) Neuroinflammation: Microglia in turn produce IL-1β, IL-6, and iNOS in a positive feedback loop.This results in unregulated overactivation leading to neurodegeneration.(3) Resting microglia: ATP secretion through Müller glial pannexin channels allows microglia to rest.CCL Chemokine (C-C motif) ligand.IL Interleukin.iNOS Inducible nitric oxide synthase.ATP Adenosine triphosphate.</p>
<p>Figure 2 .
2
Figure 2. Interaction between Müller glia and microglia.Signals from Müller glia induce changes in microglia, causing them to either rest or become activated: (1) Activated microglia: Once activated, Müller glia activate microglia by CCL2 and CCL3 secretion.(2) Neuroinflammation: Microglia in turn produce IL-1β, IL-6, and iNOS in a positive feedback loop.This results in unregulated over-activation leading to neurodegeneration.(3) Resting microglia: ATP secretion through Müller glial pannexin channels allows microglia to rest.CCL Chemokine (C-C motif) ligand.IL Interleukin.iNOS Inducible nitric oxide synthase.ATP Adenosine triphosphate.</p>
<p>Figure 3 .Figure 3 .
33
Figure 3. Morphology in the healthy neuron and the neuron of Alzheimer's disease.In Alzheimer's disease the neuron changes morphology, the dendrites are shorter, the axon is reduced decreasing the synapse, and the mitochondria become dysfunctional due to the presence of amyloid-β (Aβ) Figure3.Morphology in the healthy neuron and the neuron of Alzheimer's disease.In Alzheimer's disease the neuron changes morphology, the dendrites are shorter, the axon is reduced decreasing the synapse, and the mitochondria become dysfunctional due to the presence of amyloid-β (Aβ) plaques and neurofibrillary tangles, leading to an increase of reactive oxygen species (ROS), and subsequent cell death.</p>
<p>Figure 4 .
4
Figure 4. Healthy and dysfunctional mitochondria in the retina.The RPE/photoreceptor complex resides in a highly oxidative environment.A large number of mitochondria are located in the outer end of Müller glia, in the inner segments of photoreceptors, and in the basal part of RPE cells.The retina is a highly energy demanding organ.In healthy retinal cells, glycolysis occurs in the cytoplasm, providing pyruvate and lactate to the mitochondria where they can be substrates for acetyl-CoA synthesis, fueling the TCA cycle and electron transport chain (complex I-V) activity with final energy production in the form of ATP.In the Alzheimer's disease retina, glycolysis is affected by the amyloid-β (Aβ) peptide causing the increase in reactive oxidative species (ROS), while</p>
<p>Figure 4 .
4
Figure 4. Healthy and dysfunctional mitochondria in the retina.The RPE/photoreceptor complex resides in a highly oxidative environment.A large number of mitochondria are located in the outer end of Müller glia, in the inner segments of photoreceptors, and in the basal part of RPE cells.The retina is a highly energy demanding organ.In healthy retinal cells, glycolysis occurs in the cytoplasm, providing pyruvate and lactate to the mitochondria where they can be substrates for acetyl-CoA synthesis, fueling the TCA cycle and electron transport chain (complex I-V) activity with final energy production in the form of ATP.In the Alzheimer's disease retina, glycolysis is affected by the amyloidβ (Aβ) peptide causing the increase in reactive oxidative species (ROS), while hyperphosphorylated tau (pTau) inhibits the electron transport chain, provoking the increase of ROS inside the matrix of the mitochondria.In a harmful cycle, the increase in ROS causes mutations in mitochondrial DNA that will produce defective proteins which in turn decreases ATP and increases ROS with the subsequent oxidative stress, mitochondrial damage, and apoptosis which contribute to the retinal pathology of AD.RGC Retinal ganglion cells.AC Amacrine cells.BC Bipolar cells.MC Müller cells.HC Horizontal cells.PR Photoreceptors.RPE Retinal pigmented epithelium.I NADH reductase.II Succinate dehydrogenase.III Cytochrome complex.IV Cytochrome C oxidase.V ATP synthase.TCA cycle Tricarboxylic acid cycle.MCT Monocarboxylate transporter.ROS Reactive oxygen species.mtDNA Human mitochondrial DNA.ATP Adenosine triphosphate.ADP Adenosine diphosphate.</p>
<p>Figure 4. Healthy and dysfunctional mitochondria in the retina.The RPE/photoreceptor complex resides in a highly oxidative environment.A large number of mitochondria are located in the outer end of Müller glia, in the inner segments of photoreceptors, and in the basal part of RPE cells.The retina is a highly energy demanding organ.In healthy retinal cells, glycolysis occurs in the cytoplasm, providing pyruvate and lactate to the mitochondria where they can be substrates for acetyl-CoA synthesis, fueling the TCA cycle and electron transport chain (complex I-V) activity with final energy production in the form of ATP.In the Alzheimer's disease retina, glycolysis is affected by the amyloidβ (Aβ) peptide causing the increase in reactive oxidative species (ROS), while hyperphosphorylated tau (pTau) inhibits the electron transport chain, provoking the increase of ROS inside the matrix of the mitochondria.In a harmful cycle, the increase in ROS causes mutations in mitochondrial DNA that will produce defective proteins which in turn decreases ATP and increases ROS with the subsequent oxidative stress, mitochondrial damage, and apoptosis which contribute to the retinal pathology of AD.RGC Retinal ganglion cells.AC Amacrine cells.BC Bipolar cells.MC Müller cells.HC Horizontal cells.PR Photoreceptors.RPE Retinal pigmented epithelium.I NADH reductase.II Succinate dehydrogenase.III Cytochrome complex.IV Cytochrome C oxidase.V ATP synthase.TCA cycle Tricarboxylic acid cycle.MCT Monocarboxylate transporter.ROS Reactive oxygen species.mtDNA Human mitochondrial DNA.ATP Adenosine triphosphate.ADP Adenosine diphosphate.</p>
<p>Int. J. Mol.Sci.2023, 24, x FOR PEER REVIEW 13 of 26</p>
<p>Figure 5 .
5
Figure 5. Non-invasive imaging of the retina in Alzheimer's disease.In Alzheimer's disease patients there are visual alterations that can lead us to Alzheimer's disease diagnosis using technological tools such as optical coherence tomography (OCT), optical coherence tomography angiography (OCTA), fundus photography, and hyperspectral imaging.</p>
<p>Figure 5 .
5
Figure 5. Non-invasive imaging of the retina in Alzheimer's disease.In Alzheimer's disease patients there are visual alterations that can lead us to Alzheimer's disease diagnosis using technological tools such as optical coherence tomography (OCT), optical coherence tomography angiography (OCTA), fundus photography, and hyperspectral imaging.</p>
<p>Table 1 .
1
Alzheimer's-related findings in both brain and retina of human and animal models.</p>
<p>Table 1 .
1
Alzheimer's-related findings in both brain and retina of human and animal models.
FindingsIn Vitro In VivoReferenceMouseRetinaAβ plaquesXX[60,97,98]pTau, tau accumulation, and NFTsX[99-101]RGC loss/RNFL thinningXX[60,61,102,103]Energetic, metabolic, and mitochondrial dysfunctionX[19,33,89,104-106]Microglia activationX[15,33,107]Müller glia activationX[33,97,105]BrainAβ plaquesX[103,108]pTau, tau accumulation, and NFTsX[13,109-111]Energetic, metabolic, and mitochondrial dysfunctionX[106,112-114]Microglia activationXX[12,13,79,93,114-117]Increased oxidative stressXX[112,118,119]HumanRetinaAβ plaquesXX[29-31,38,63,66]pTau and NFTsXX[29,38,70]Visual impairmentXX[45,120]RGC loss/RNFL thinningXX[45,59,121-123]Energetic, metabolic, and mitochondrial dysfunctionX[104]Microglia activationX[15,18,33,124]Müller glia activationX[15,95]Increased oxidative stressX[15,122]BrainAβ plaquesXX[4,5,117,125]pTau and NFTsXX[4,5,125,126]Energetic, metabolic, and mitochondrial dysfunctionXX[6,118,126-131]Microglia and neuron activationX[12,18,112,117,132,133]Increased oxidative stressXX[17,113,134,135]</p>
<p>Table 2 .
2
Comparison of Alzheimer's disease with Diabetic Retinopathy, Glaucoma, and Age-Related Macular Degeneration.
Alzheimer's DiseaseDiabetic RetinopathyGlaucomaAge-Related Macular DegenerationNeurodegenerationPresentYes [167]PresentYes [168]VascularizationYesYesYesYesVision ImpairmentProgressive declineVision lossPeripheral vision lossCentral vision lossRisk FactorsAge, geneticsDiabetes, hypertension, obesityAge, family historyAge, geneticsProteins and pathwaysAβYes [169]
Funding: This work was supported by the Department of Drug Design and Pharmacology at the University of Copenhagen, the BRIDGE-Translational Excellence Program funded by the Novo Nordisk Foundation (Grant agreement no.NNF18SA0034956), the Foundation for Research in Neurology and Innovation Foundation Denmark grant 2078-00002B StemScreen (K.Freude), and the Savvaerksejer Jeppe Juhls og hustru Ovita Juhls Mindelegat.The present review is part of the Doctoral studies of M. Y. García-Bermúdez MSc, who is a student at the University of Copenhagen.She was supported by the ILF group and CONACYT doctoral scholarship CVU: 859376.
The natural history of cognitive decline in Alzheimer's disease. R S Wilson, E Segawa, P A Boyle, S E Anagnos, L P Hizel, D A Bennett, 10.1037/a0029857Psychol. Aging. 272012</p>
<p>Alzheimer's disease facts and figures. 10.1016/j.jalz.2016.03.0012016. 201612Alzheimer's Dement</p>
<p>Alzheimer's Disease Therapeutic Approaches. M Revi, 10.1007/978-3-030-32633-3_15GeNeDis. Cham, SwitzerlandSpringer2018. 2018</p>
<p>Alzheimer's disease. C A Lane, J Hardy, J M Schott, 10.1111/ene.13439Eur. J. Neurol. 252018</p>
<p>The physiological roles of tau and Aβ: Implications for Alzheimer's disease pathology and therapeutics. S A Kent, T L Spires-Jones, C S Durrant, 10.1007/s00401-020-02196-wActa Neuropathol. 1402020</p>
<p>Alzheimer's as a metabolic disease. L A Demetrius, J Driver, 10.1007/s10522-013-9479-7Biogerontology. 142013</p>
<p>Alzheimer's disease: The amyloid cascade hypothesis. J A Hardy, G A Higgins, 10.1126/science.1566067Science. 2561992</p>
<p>The IL-1beta phenomena in neuroinflammatory diseases. A S Mendiola, A E Cardona, J. Neural Transm. 1252018</p>
<p>Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. A R Nelson, M D Sweeney, A P Sagare, B V Zlokovic, 10.1016/j.bbadis.2015.12.016Biochim. Biophys. Acta. 18622016</p>
<p>Microglia in Alzheimer's disease. D V Hansen, J E Hanson, M Sheng, 10.1083/jcb.201709069J. Cell Biol. 2172018</p>
<p>Neuroinflammation in Alzheimer's disease: Current evidence and future directions. V Calsolaro, P Edison, 10.1016/j.jalz.2016.02.010201612Alzheimer's Dement</p>
<p>D Tejera, M T Heneka, Microglia in Neurodegenerative Disorders. 2019. 2034</p>
<p>Depletion of microglia and inhibition of exosome synthesis halt tau propagation. H Asai, S Ikezu, S Tsunoda, M Medalla, J Luebke, T Haydar, B Wolozin, O Butovsky, S Kugler, T Ikezu, 10.1038/nn.4132Nat. Neurosci. 182015</p>
<p>A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. H Keren-Shaul, A Spinrad, A Weiner, O Matcovitch-Natan, R Dvir-Szternfeld, T K Ulland, E David, K Baruch, D Lara-Astaiso, B Toth, 10.1016/j.cell.2017.05.0182017. 1276-1290.e1217169</p>
<p>Contribution of microglia-mediated neuroinflammation to retinal degenerative diseases. M H Madeira, R Boia, P F Santos, A F Ambrosio, A R Santiago, 10.1155/2015/673090Mediat. Inflamm. 6730902015. 2015</p>
<p>The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review. S Manoharan, G J Guillemin, R S Abiramasundari, M M Essa, M Akbar, M D Akbar, 10.1155/2016/8590578Oxid. Med. Cell Longev. 85905782016. 2016</p>
<p>Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer's Disease. F Cioffi, R H I Adam, K Broersen, 10.3233/JAD-190863J. Alzheimer's Dis. 722019</p>
<p>The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma. Front. Aging Neurosci. A I Ramirez, R De Hoz, E Salobrar-Garcia, J J Salazar, B Rojas, D Ajoy, I Lopez-Cuenca, P Rojas, A Trivino, J M Ramirez, 10.3389/fnagi.2017.0021420179214</p>
<p>Decreased Glucose Metabolism and Glutamine Synthesis in the Retina of a Transgenic Mouse Model of Alzheimer's Disease. A L M Tams, B Sanz-Morello, E W Westi, Z A Mouhammad, J V Andersen, K K Freude, R Vohra, J Hannibal, B I Aldana, M Kolko, 10.1007/s10571-021-01126-yCell. Mol. Neurobiol. 422021</p>
<p>Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction. Y Compta, T Revesz, 10.3233/JPD-202323J. Park. Dis. 112021</p>
<p>The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. O Hansson, R M Edelmayer, A L Boxer, M C Carrillo, M M Mielke, G D Rabinovici, S Salloway, R Sperling, H Zetterberg, C E Teunissen, 10.1002/alz.12756202218Alzheimer's Dement</p>
<p>Alzheimer's Disease: Epidemiology and Clinical Progression. A A Tahami Monfared, M J Byrnes, L A White, Q Zhang, 10.1007/s40120-022-00338-8Neurol. Ther. 2022</p>
<p>Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. E Zamrini, S De Santi, M Tolar, 10.1016/j.neurobiolaging.2004.02.009Neurobiol. Aging. 252004</p>
<p>Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. A Lleo, R Nunez-Llaves, D Alcolea, C Chiva, D Balateu-Panos, M Colom-Cadena, G Gomez-Giro, L Munoz, M Querol-Vilaseca, J Pegueroles, 10.1074/mcp.RA118.001290Mol. Cell Proteom. 182019</p>
<p>New molecular approaches to Alzheimer's disease. C Di Resta, M Ferrari, 10.1016/j.clinbiochem.2019.04.010Clin. Biochem. 722019</p>
<p>Altered tau and neurofilament proteins in neuro-degenerative diseases: Diagnostic implications for Alzheimer's disease and Lewy body dementias. J Q Trojanowski, M L Schmidt, R W Shin, G T Bramblett, D Rao, V M Lee, 10.1111/j.1750-3639.1993.tb00725.xBrain Pathol. 31993</p>
<p>Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021. A P Porsteinsson, R S Isaacson, S Knox, M N Sabbagh, I Rubino, 10.14283/jpad.2021.23J. Prev. Alzheimers Dis. 82021</p>
<p>Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. B Dubois, H H Feldman, C Jacova, H Hampel, J L Molinuevo, K Blennow, S T Dekosky, S Gauthier, D Selkoe, R Bateman, Lancet Neurol. 132014</p>
<p>Ocular indicators of Alzheimer's: Exploring disease in the retina. N J Hart, Y Koronyo, K L Black, M Koronyo-Hamaoui, 10.1007/s00401-016-1613-6Acta Neuropathol. 1322016</p>
<p>Alzheimer's disease in the retina: Imaging retinal abeta plaques for early diagnosis and therapy assessment. Y Koronyo, B C Salumbides, K L Black, M Koronyo-Hamaoui, 10.1159/000335154Neurodegener. Dis. 102012</p>
<p>Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. Y Koronyo, D Biggs, E Barron, D S Boyer, J A Pearlman, W J Au, S J Kile, A Blanco, D T Fuchs, A Ashfaq, 10.1172/jci.insight.93621JCI Insight. 22017e93621. [CrossRef</p>
<p>The Interaction Between Microglia and Macroglia in Glaucoma. X Zhao, R Sun, X Luo, F Wang, X Sun, 10.3389/fnins.2021.610788Front. Neurosci. 156107882021</p>
<p>M Y Garcia-Bermudez, K K Freude, Z A Mouhammad, P Van Wijngaarden, K K Martin, M Kolko, 10.3389/fneur.2021.624983Glial Cells in Glaucoma: Friends, Foes, and Potential Therapeutic Targets. 202112624983</p>
<p>Dual Properties of Lactate in Muller Cells: The Effect of GPR81 Activation. R Vohra, B I Aldana, H Waagepetersen, L H Bergersen, M Kolko, 10.1167/iovs.18-25458Investig. Ophthalmol. Vis. Sci. 602019</p>
<p>Energy metabolism in human retinal Muller cells. B S Winkler, M J Arnold, M A Brassell, D G Puro, Investig. Ophthalmol. Vis. Sci. 412000</p>
<p>Mitochondrial function in Muller cells-Does it matter? Mitochondrion. A K Toft-Kehler, D M Skytt, A Svare, E Lefevere, I Van Hove, L Moons, H S Waagepetersen, M Kolko, 10.1016/j.mito.2017.02.002201736</p>
<p>Oxidative Stress-Induced Dysfunction of Müller Cells During Starvation. A K Toft-Kehler, I S Gurubaran, C Desler, L J Rasmussen, D M Skytt, M Kolko, 10.1167/iovs.16-19275Investig. Opthalmol. Vis. Sci. 572016. 2721</p>
<p>Visual and Ocular Manifestations of Alzheimer's Disease and Their Use as Biomarkers for Diagnosis and Progression. F Z Javaid, J Brenton, L Guo, M F Cordeiro, 10.3389/fneur.2016.00055Front. Neurol. 2016, 7, 55. [CrossRef</p>
<p>Alzheimer's Disease Seen through the Eye: Ocular Alterations and Neurodegeneration. D Romaus-Sanjurjo, U Regueiro, M Lopez-Lopez, L Vazquez-Vazquez, A Ouro, I Lema, T Sobrino, 10.3390/ijms23052486Int. J. Mol. Sci. 232022. 2486</p>
<p>Pupillary Responses as a Biomarker of Early Risk for Alzheimer's Disease. E L Granholm, M S Panizzon, J A Elman, A J Jak, R L Hauger, M W Bondi, M J Lyons, C E Franz, W S Kremen, 10.3233/JAD-161078201756Alzheimer's Dis</p>
<p>Light-Induced Pupillary Responses in Alzheimer's Disease. P S Chougule, R P Najjar, M T Finkelstein, N Kandiah, D Milea, 10.3389/fneur.2019.00360Front. Neurol. 102019</p>
<p>Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. L E Goldstein, J A Muffat, R A Cherny, R D Moir, M H Ericsson, X Huang, C Mavros, J A Coccia, K Y Faget, K A Fitch, 10.1016/S0140-6736(03)12981-9Lancet. 3612003</p>
<p>Beta-Amyloid, Phospho-Tau and Alpha-Synuclein Deposits Similar to Those in the Brain Are Not Identified in the Eyes of Alzheimer's and Parkinson's Disease Patients. C.-Y Ho, J C Troncoso, D Knox, W Stark, C G Eberhart, 10.1111/bpa.12070Brain Pathol. 242014</p>
<p>Axonal Terminals Exposed to Amyloid-β May Not Lead to Pre-Synaptic Axonal Damage. S.-W Sun, C Nishioka, W Labib, H.-F Liang, 10.3233/JAD-142154J. Alzheimer's Dis. 452015</p>
<p>Alzheimer's disease in the human eye. Clinical tests that identify ocular and visual information processing deficit as biomarkers. L Y L Chang, J Lowe, A Ardiles, J Lim, A C Grey, K Robertson, H Danesh-Meyer, A G Palacios, M L Acosta, 10.1016/j.jalz.2013.06.0042014Alzheimer's Dement10</p>
<p>Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia. W J Deardorff, G T Grossberg, Handb. Clin. Neurol. 1652019</p>
<p>Use of ocular biomarkers as a potential tool for early diagnosis of Alzheimer's disease. A K Singh, S Verma, 10.4103/ijo.IJO_999_19Indian. J. Ophthalmol. 682020</p>
<p>. A Majeed, B Marwick, H Yu, H Fadavi, M Tavakoli, 10.3389/fnagi.2021.720167Ophthalmic Biomarkers for Alzheimer's Disease: A Review. Front. Aging Neurosci. 132021. 720167</p>
<p>Past, present and future role of retinal imaging in neurodegenerative disease. A H Kashani, S Asanad, J W Chan, M B Singer, J Zhang, M Sharifi, M M Khansari, F Abdolahi, Y Shi, A Biffi, 10.1016/j.preteyeres.2020.100938Prog. Retin. Eye Res. 832021. 100938</p>
<p>Vertebrate retina and hypothalamus development. M S Byerly, S Blackshaw, 10.1002/wsbm.22Wiley Interdiscip. Rev. Syst. Biol. Med. 12009</p>
<p>. J L Dreyfuss, R J Giordano, C V Regatieri, Ocular, 10.1155/2015/892043Angiogenesis. J. Ophthalmol. 8920432015. 2015</p>
<p>Retinal Vascular Changes in Alzheimer's Dementia and Mild Cognitive Impairment: A Pilot Study Using Ultra-Widefield Imaging. E Pead, A C Thompson, D S Grewal, S Mcgrory, C B Robbins, J P Ma, K G Johnson, A J Liu, C Hamid, E Trucco, 10.1167/tvst.12.1.13Transl. Vis. Sci. Technol. 122023</p>
<p>The application of optical coherence tomography angiography in Alzheimer's disease: A systematic review. O M Rifai, S Mcgrory, C B Robbins, D S Grewal, A Liu, S Fekrat, T J Macgillivray, 10.1002/dad2.121492021. e1214913Alzheimer's Dement</p>
<p>Retinal Vasculopathy in Alzheimer's Disease. H Shi, Y Koronyo, A Rentsendorj, D T Fuchs, J Sheyn, K L Black, N Mirzaei, M Koronyo-Hamaoui, 10.3389/fnins.2021.731614Front. Neurosci. 152021. 731614</p>
<p>Vascular Dysfunction in Alzheimer's Disease: A Prelude to the Pathological Process or a Consequence of It?. K Govindpani, L G Mcnamara, N R Smith, C Vinnakota, H J Waldvogel, R L Faull, A Kwakowsky, 10.3390/jcm8050651J. Clin. Med. 86512019</p>
<p>The retinal pigment epithelium: Something more than a constituent of the blood-retinal barrier-implications for the pathogenesis of diabetic retinopathy. R Simo, M Villarroel, L Corraliza, C Hernandez, M Garcia-Ramirez, 10.1155/2010/190724J. Biomed. Biotechnol. 2010. 2010. 190724</p>
<p>Retinal Anatomy and Pathology. M P Gupta, A A Herzlich, T Sauer, C C Chan, Dev. Ophthalmol. 552016</p>
<p>Identification of early-onset photoreceptor degeneration in transgenic mouse models of Alzheimer's disease. J Zhang, F Gao, Y Ma, T Xue, Y Shen, 10.1016/j.isci.2021.1033272021. 10332724</p>
<p>Correlation between brain volume and retinal photoreceptor outer segment volume in normal aging and neurodegenerative diseases. A Uchida, J A Pillai, R Bermel, S E Jones, H Fernandez, J B Leverenz, S K Srivastava, J P Ehlers, 10.1371/journal.pone.0237078PLoS ONE. 152020. e0237078</p>
<p>Retinal Functional and Structural Changes in the 5xFAD Mouse Model of Alzheimer's Disease. J K H Lim, Q X Li, Z He, A J Vingrys, H R Chinnery, J Mullen, B V Bui, C T O Nguyen, 10.3389/fnins.2020.00862Front. Neurosci. 142020</p>
<p>Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. S E Perez, S Lumayag, B Kovacs, E J Mufson, S Xu, 10.1167/iovs.08-2384Investig. Ophthalmol. Vis. Sci. 502009</p>
<p>Changes in visual function and retinal structure in the progression of Alzheimer's disease. E Salobrar-García, R De Hoz, A I Ramírez, I López-Cuenca, P Rojas, R Vazirani, C Amarante, R Yubero, P Gil, M D Pinazo-Durán, 10.1371/journal.pone.0220535PLoS ONE. 142019. e0220535</p>
<p>Alzheimer's Retinopathy: Seeing Disease in the Eyes. N Mirzaei, H Shi, M Oviatt, J Doustar, A Rentsendorj, D T Fuchs, J Sheyn, K L Black, Y Koronyo, M Koronyo-Hamaoui, 10.3389/fnins.2020.00921Front. Neurosci. 149212020</p>
<p>Melanopsin retinal ganglion cell loss in Alzheimer disease. La Morgia, C Ross-Cisneros, F N Koronyo, Y Hannibal, J Gallassi, R Cantalupo, G Sambati, L Pan, B X Tozer, K R Barboni, P , 10.1002/ana.24548Ann. Neurol. 792016</p>
<p>Ganglion Cell Layer Thinning in Alzheimer's Disease. A Lopez-De-Eguileta, A Cervero, A Ruiz De Sabando, P Sanchez-Juan, A Casado, 10.3390/medicina56100553202056Medicina</p>
<p>Amyloid Beta Immunoreactivity in the Retinal Ganglion Cell Layer of the Alzheimer's Eye. S Lee, K Jiang, B Mcilmoyle, E To, Q A Xu, V Hirsch-Reinshagen, I R Mackenzie, G R Hsiung, B D Eadie, M V Sarunic, 10.3389/fnins.2020.00758Front. Neurosci. 142020</p>
<p>Parallels between retinal and brain pathology and response to immunotherapy in old, late-stage Alzheimer's disease mouse models. J Doustar, A Rentsendorj, T Torbati, G C Regis, D T Fuchs, J Sheyn, N Mirzaei, S L Graham, P K Shah, M Mastali, 10.1111/acel.13246Aging Cell. 192020. e13246</p>
<p>Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer's disease in the 3xTg-AD mouse model. A Grimaldi, C Brighi, G Peruzzi, D Ragozzino, V Bonanni, C Limatola, G Ruocco, S Di Angelantonio, 10.1038/s41419-018-0740-5Cell Death Dis. 96852018</p>
<p>Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. M Koronyo-Hamaoui, Y Koronyo, A V Ljubimov, C A Miller, M K Ko, K L Black, M Schwartz, D L Farkas, 10.1016/j.neuroimage.2010.06.020Neuroimage. 542011Suppl. S1)</p>
<p>Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. J Den Haan, T H J Morrema, F D Verbraak, J F De Boer, P Scheltens, A J Rozemuller, A A B Bergen, F H Bouwman, J J Hoozemans, 10.1186/s40478-018-0650-xActa Neuropathol. Commun. 61472018</p>
<p>Origin of microglia: Current concepts and past controversies. F Ginhoux, M Prinz, 10.1101/cshperspect.a020537Cold Spring Harb. Perspect. Biol. 72015a020537. [CrossRef</p>
<p>Retinal microglia: Functions and diseases. W Fan, W Huang, J Chen, N Li, L Mao, S Hou, 10.1111/imm.13479Immunology. 1662022</p>
<p>Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models. E E Spangenberg, K N Green, 10.1016/j.bbi.2016.07.003Brain Behav. Immun. 612017</p>
<p>Displacement of synaptic terminals from regenerating motoneurons by microglial cells. K Blinzinger, G Kreutzberg, 10.1007/BF00325030Z. Zellforsch. Mikrosk. Anat. 851968</p>
<p>New roles for the synaptic stripper. H Kettenmann, F Kirchhoff, A Verkhratsky, Microglia, 10.1016/j.neuron.2012.12.023Neuron. 772013</p>
<p>Neurons under T Cell Attack Coordinate Phagocyte-Mediated Synaptic Stripping. G Di Liberto, S Pantelyushin, M Kreutzfeldt, N Page, S Musardo, R Coras, K Steinbach, I Vincenti, B Klimek, T Lingner, 10.1016/j.cell.2018.07.049Cell. 1752018e419. [CrossRef</p>
<p>The role of microglia in synaptic stripping and synaptic degeneration: A revised perspective. V H Perry, V O'connor, 10.1042/AN20100024ASN Neuro. 22010e00047. [CrossRef</p>
<p>Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). Y Atagi, C C Liu, M M Painter, X F Chen, C Verbeeck, H Zheng, X Li, R Rademakers, S S Kang, H Xu, 10.1074/jbc.M115.679043J. Biol. Chem. 2902015</p>
<p>TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Y Wang, M Cella, K Mallinson, J D Ulrich, K L Young, M L Robinette, S Gilfillan, G M Krishnan, S Sudhakar, B H Zinselmeyer, 10.1016/j.cell.2015.01.049Cell. 1602015</p>
<p>The Pathophysiological Role of Microglia in Dynamic Surveillance, Phagocytosis and Structural Remodeling of the Developing CNS. C Arcuri, C Mecca, R Bianchi, I Giambanco, R Donato, 10.3389/fnmol.2017.00191Front. Mol. Neurosci. 102017. 191</p>
<p>Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. M L Block, J S Hong, 10.1016/j.pneurobio.2005.06.004Prog. Neurobiol. 762005</p>
<p>CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation. E G Reed-Geaghan, J C Savage, A G Hise, G E Landreth, 10.1523/JNEUROSCI.3158-09.2009J. Neurosci. 292009</p>
<p>Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis. D Doens, P L Fernández, 10.1186/1742-2094-11-48J. Neuroinflamm. 112014</p>
<p>Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease. M Fiala, R Veerhuis, 10.1016/j.exger.2009.08.003Exp. Gerontol. 452010</p>
<p>Müller Glia Reactivity and Development of Gliosis in Response to Pathological Conditions. A B Graca, C Hippert, R A Pearson, 2018Springer International Publishing: Berlin/HeidelbergGermany</p>
<p>Microglia-Müller Cell Interactions in the Retina. M Wang, W T Wong, 2014SpringerNew York, NY, USA</p>
<p>New functions of Muller cells. A Reichenbach, A Bringmann, 10.1002/glia.22477Glia. 612013</p>
<p>Neuroprotection of the inner retina: Muller cells and lactate. R Vohra, M Kolko, Neural Regen. Res. 132018</p>
<p>Lactate: More Than Merely a Metabolic Waste Product in the Inner Retina. R Vohra, M Kolko, 10.1007/s12035-019-01863-8Mol. Neurobiol. 572020</p>
<p>Lactate-Mediated Protection of Retinal Ganglion Cells. R Vohra, B I Aldana, G Bulli, D M Skytt, H Waagepetersen, L H Bergersen, M Kolko, 10.1016/j.jmb.2019.03.005J. Mol. Biol. 4312019</p>
<p>Essential Roles of Lactate in Muller Cell Survival and Function. R Vohra, B I Aldana, D M Skytt, K Freude, H Waagepetersen, L H Bergersen, M Kolko, 10.1007/s12035-018-1056-2Mol. Neurobiol. 552018</p>
<p>GABA and Glutamate Uptake and Metabolism in Retinal Glial. A Bringmann, A Grosche, T Pannicke, A Reichenbach, 10.3389/fendo.2013.00048Muller) Cells. Front. Endocrinol. 2013, 4, 48</p>
<p>Reciprocal Regulation between Resting Microglial Dynamics and Neuronal Activity In Vivo. Y Li, X.-F Du, C.-S Liu, Z.-L Wen, J.-L Du, 10.1016/j.devcel.2012.10.027Dev. Cell. 232012</p>
<p>Differential Effects of Intra-and Extravascular ATP on the Diameter of Porcine Vessels at Different Branching Levels Ex Vivo. C Ernst, P Skov Jensen, C Aalkjaer, T Bek, 10.1167/iovs.61.12.8Investig. Ophthalmol. Vis. Sci. 612020</p>
<p>Microglia-Muller cell interactions in the retina. M Wang, W T Wong, Adv. Exp. Med. Biol. 8012014</p>
<p>Microglial Activation in the Retina of a Triple-Transgenic Alzheimer's Disease Mouse Model (3xTg-AD). E Salobrar-Garcia, A C Rodrigues-Neves, A I Ramirez, R De Hoz, J A Fernandez-Albarral, I Lopez-Cuenca, J M Ramirez, A F Ambrosio, J J Salazar, 10.3390/ijms21030816Int. J. Mol. Sci. 212020</p>
<p>Retinal macroglia changes in a triple transgenic mouse model of Alzheimer's disease. Exp. M M Edwards, J J Rodríguez, R Gutierrez-Lanza, J Yates, A Verkhratsky, G A Lutty, 10.1016/j.exer.2014.08.006Eye Res. 1272014</p>
<p>Investigations into Retinal Pathology in the Early Stages of a Mouse Model of Alzheimer's Disease. J. Alzheimer's Dis. G Chidlow, J P Wood, J Manavis, J Finnie, R J Casson, 10.3233/JAD-160823201756</p>
<p>Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease. Cells. P H Reddy, D M Oliver, 10.3390/cells805048820198488</p>
<p>Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer's disease. M Chiasseu, L Alarcon-Martinez, N Belforte, H Quintero, F Dotigny, L Destroismaisons, C Vande Velde, F Panayi, C Louis, A Di Polo, 10.1186/s13024-017-0199-3Mol. Neurodegener. 122017</p>
<p>Ginsenoside Rg1 Decreases Neurofibrillary Tangles Accumulation in Retina by Regulating Activities of Neprilysin and PKA in Retinal Cells of AD Mice Model. Y He, H Zhao, G Su, 10.1007/s12031-013-0173-7J. Mol. Neurosci. 522014</p>
<p>Neurodegeneration of the retina in mouse models of Alzheimer's disease: What can we learn from the retina? Age. K Chiu, T F Chan, A Wu, I Y Leung, K F So, R C Chang, 10.1007/s11357-011-9260-2201234</p>
<p>Retinal changes in the Tg-SwDI mouse model of Alzheimer's disease. F G Oliveira-Souza, M L Deramus, T Van Groen, A E Lambert, M S Bolding, C E Strang, 10.1016/j.neuroscience.2017.04.0212017354</p>
<p>Retinal metabolism: A comparative look at energetics in the retina. M W Country, 10.1016/j.brainres.2017.07.025Brain Res. 16722017</p>
<p>Mitochondria of retinal Muller (glial) cells: The effects of aging and of application of free radical scavengers. G Paasche, U Gartner, A Germer, J Grosche, A Reichenbach, 10.1159/000055618Ophthalmic Res. 322000</p>
<p>Lactate Transport and Receptor Actions in Retina: Potential Roles in Retinal Function and Disease. M Kolko, F Vosborg, U L Henriksen, M M Hasan-Olive, E H Diget, R Vohra, I R S Gurubaran, A Gjedde, S T Mariga, D M Skytt, 10.1007/s11064-015-1792-xNeurochem. Res. 412016</p>
<p>APP Modulates Abeta-Induced Activation of Microglia in Mouse Model of Alzheimer's Disease. D Datta, 10.1523/JNEUROSCI.3122-16.2017J. Neurosci. 372017</p>
<p>Deficient astrocyte metabolism impairs glutamine synthesis and neurotransmitter homeostasis in a mouse model of Alzheimer's disease. J V Andersen, S K Christensen, E W Westi, M Diaz-Delcastillo, H Tanila, A Schousboe, B I Aldana, H S Waagepetersen, 10.1016/j.nbd.2020.105198Neurobiol. Dis. 1482021. 105198</p>
<p>Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer's disease. R Kandimalla, M Manczak, X Yin, R Wang, P H Reddy, Hum. Mol. Genet. 272018</p>
<p>Markers of Alzheimer's Disease in Primary Visual Cortex in Normal Aging in Mice. L F Hernández-Zimbrón, M Perez-Hernández, A Torres-Romero, E Gorostieta-Salas, R Gonzalez-Salinas, R Gulias-Cañizo, H Quiroz-Mercado, E Zenteno, 10.1155/2017/3706018BioMed Res. Int. 37060182017, 2017</p>
<p>Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. M Iba, J L Guo, J D Mcbride, B Zhang, J Q Trojanowski, V M Lee, 10.1523/JNEUROSCI.2642-12.2013J. Neurosci. 332013</p>
<p>A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease. S H Baik, S Kang, W Lee, H Choi, S Chung, J.-I Kim, I Mook-Jung, 10.1016/j.cmet.2019.06.005Cell Metab. 302019e496. [CrossRef</p>
<p>Stress: A Key Modulator in Neurodegenerative Diseases. A Singh, R Kukreti, L Saso, S Kukreti, Oxidative, 10.3390/molecules24081583Molecules. 242019. 1583</p>
<p>ATP mediates rapid microglial response to local brain injury in vivo. D Davalos, J Grutzendler, G Yang, J V Kim, Y Zuo, S Jung, D R Littman, M L Dustin, W B Gan, 10.1038/nn1472Nat. Neurosci. 82005</p>
<p>NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. M T Heneka, M P Kummer, A Stutz, A Delekate, S Schwartz, A Vieira-Saecker, A Griep, D Axt, A Remus, T.-C Tzeng, 10.1038/nature11729Nature. 4932013</p>
<p>J Yin, F Zhao, J E Chojnacki, J Fulp, W L Klein, S Zhang, X Zhu, 10.1007/s12035-017-0467-9NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer's Disease. 2018. 1977-198755</p>
<p>neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Z Cai, M D Hussain, L.-J Yan, Microglia, 10.3109/00207454.2013.833510Int. J. Neurosci. 1242014</p>
<p>Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Z Chen, C Zhong, 10.1016/j.pneurobio.2013.06.004Prog. Neurobiol. 1082013</p>
<p>Abeta and tau toxicities in Alzheimer's are linked via oxidative stress-induced p38 activation: Protective role of vitamin E. E Giraldo, A Lloret, T Fuchsberger, J Vina, 10.1016/j.redox.2014.03.002Redox Biol. 22014</p>
<p>Retinal ganglion cell degeneration in Alzheimer's disease. J C Blanks, D R Hinton, A A Sadun, C A Miller, 10.1016/0006-8993(89)90653-7Brain Res. 5011989</p>
<p>Ganglion cell layer thinning in prodromal Alzheimer's disease defined by amyloid PET. Alzheimer's Dement. A Lopez-De-Eguileta, C Lage, S Lopez-Garcia, A Pozueta, M Garcia-Martinez, M Kazimierczak, M Bravo, M De Arcocha-Torres, I Banzo, J Jimenez-Bonilla, 10.1016/j.trci.2019.08.00820195</p>
<p>Retinal Degeneration and Alzheimer's Disease: An Evolving Link. A Ashok, N Singh, S Chaudhary, V Bellamkonda, A E Kritikos, A S Wise, N Rana, D Mcdonald, R Ayyagari, 10.3390/ijms21197290Int. J. Mol. Sci. 212020</p>
<p>Retinal alterations in mild cognitive impairment and Alzheimer's disease: An optical coherence tomography study. F J Ascaso, N Cruz, P J Modrego, R Lopez-Anton, J Santabarbara, L F Pascual, A Lobo, J A Cristobal, J. Neurol. 2612014</p>
<p>. K Rashid, I Akhtar-Schaefer, T Langmann, 10.3389/fimmu.2019.01975Microglia in Retinal Degeneration. Front. Immunol. 102019. 1975</p>
<p>The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. G M Mckhann, D S Knopman, H Chertkow, B T Hyman, C R Jack, Jr, C H Kawas, W E Klunk, W J Koroshetz, J J Manly, R Mayeux, 10.1016/j.jalz.2011.03.0052011Alzheimer's Dement7</p>
<p>Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer's Disease. J. Alzheimer's Dis. Q Cai, P Tammineni, 201757</p>
<p>A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. I Maurer, S Zierz, H J Moller, 10.1016/S0197-4580(00)00112-3Neurobiol. Aging. 212000</p>
<p>Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. F G De Felice, S T Ferreira, 10.2337/db13-1954Diabetes. 632014</p>
<p>Mitochondrial Dysfunction-A Pharmacological Target in Alzheimer's Disease. G P Eckert, K Renner, S H Eckert, J Eckmann, S Hagl, R M Abdel-Kader, C Kurz, K Leuner, W E Muller, 10.1007/s12035-012-8271-zMol. Neurobiol. 462012</p>
<p>Alzheimer's disease: Diverse aspects of mitochondrial malfunctioning. R X Santos, S C Correia, X Wang, G Perry, M A Smith, P I Moreira, X Zhu, Int. J. Clin. Exp. Pathol. 32010</p>
<p>Mechanisms of Mitochondrial Dysfunction in Alzheimer's Disease. C Cadonic, M G Sabbir, B C Albensi, 10.1007/s12035-015-9515-5Mol. Neurobiol. 532016</p>
<p>Tau-66: Evidence for a novel tau conformation in Alzheimer's disease. N Ghoshal, F García-Sierra, Y Fu, L A Beckett, E J Mufson, J Kuret, R W Berry, L I Binder, 10.1046/j.1471-4159.2001.00346.xJ. Neurochem. 772001</p>
<p>Local neuroinflammation and the progression of Alzheimer's disease. P L Mcgeer, E G Mcgeer, J. Neurovirol. 82002</p>
<p>Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. F G De Felice, P T Velasco, M P Lambert, K Viola, S J Fernandez, S T Ferreira, W L Klein, 10.1074/jbc.M607483200J. Biol. Chem. 2822007</p>
<p>Imaging for Oxidative Stress in Neurodegenerative Disorders Associated with Mitochondrial Dysfunction. Antioxidants. M Ikawa, H Okazawa, Y Nakamoto, M Yoneda, 10.3390/antiox909086120209861</p>
<p>Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. C R Jack, Jr, M S Albert, D S Knopman, G M Mckhann, R A Sperling, M C Carrillo, B Thies, C H Phelps, 10.1016/j.jalz.2011.03.0042011Alzheimer's Dement7</p>
<p>Retinal Vascular Abnormalities in Patients with Cerebral Amyloid Angiopathy. A Lee, A Rudkin, M Agzarian, S Patel, S Lake, C Chen, 10.1159/000251173Cerebrovasc. Dis. 282009</p>
<p>Role of Retinal Amyloid-beta in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications. L Wang, X Mao, 10.3390/ijms22052360Int. J. Mol. Sci. 222021. 2360</p>
<p>Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. J C Blanks, S Y Schmidt, Y Torigoe, K V Porrello, D R Hinton, R H Blanks, 10.1016/0197-4580(96)00009-7Neurobiol. Aging. 171996</p>
<p>Hippocampal disruptions of synaptic and astrocyte metabolism are primary events of early amyloid pathology in the 5xFAD mouse model of Alzheimer's disease. J V Andersen, N H Skotte, S K Christensen, F S Polli, M Shabani, K H Markussen, H Haukedal, E W Westi, M Diaz-Delcastillo, R C Sun, 10.1038/s41419-021-04237-yCell Death Dis. 2021, 12, 954. [CrossRef</p>
<p>A Metabolic Landscape for Maintaining Retina Integrity and Function. F O Viegas, S C F Neuhauss, 10.3389/fnmol.2021.656000Front. Mol. Neurosci. 142021</p>
<p>Van Hove, I. Mitochondrial dysfunction underlying outer retinal diseases. E Lefevere, A K Toft-Kehler, R Vohra, M Kolko, L Moons, 10.1016/j.mito.2017.03.006201736</p>
<p>Mitochondrial Dysfunction in Neurodegenerative Diseases. A Johri, M F Beal, J. Pharmacol. Exp. Ther. 3422012</p>
<p>Mitochondrial fission, fusion, and stress. R J Youle, A M Van Der Bliek, 10.1126/science.1219855Science. 3372012</p>
<p>Mitochondrial medicine for aging and neurodegenerative diseases. P H Reddy, 10.1007/s12017-008-8044-zNeuromol. Med. 102008</p>
<p>Mitochondrial dynamics in Alzheimer's disease: Opportunities for future treatment strategies. D J Bonda, X Wang, G Perry, M A Smith, X Zhu, 10.2165/11532140-000000000-00000Drugs Aging. 272010</p>
<p>The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. X Wang, B Su, L Zheng, G Perry, M A Smith, X Zhu, 10.1111/j.1471-4159.2009.05867.xJ. Neurochem. 1092009Suppl. S1</p>
<p>Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to Alzheimer's disease. J Hroudova, N Singh, Z Fisar, 10.1155/2014/175062Biomed. Res. Int. 2014. 2014. 175062</p>
<p>Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. X Wang, B Su, H G Lee, X Li, G Perry, M A Smith, X Zhu, 10.1523/JNEUROSCI.1357-09.2009J. Neurosci. 292009</p>
<p>A cell model for the initial phase of sporadic Alzheimer's disease. C Stockburger, V A Gold, T Pallas, N Kolesova, D Miano, K Leuner, W E Muller, 10.3233/JAD-140381J. Alzheimer's Dis. 422014</p>
<p>Alzheimer's disease: Effects of β-amyloid on mitochondria. L Tillement, L Lecanu, V Papadopoulos, 10.1016/j.mito.2010.08.009201111</p>
<p>Mitochondrial Function, Dynamics, and Permeability Transition: A Complex Love Triangle as A Possible Target for the Treatment of Brain Aging and Alzheimer's Disease. C Stockburger, S Eckert, G P Eckert, K Friedland, W E Muller, 10.3233/JAD-179915J. Alzheimer's Dis. 642018</p>
<p>Cyclophilin D deficiency rescues axonal mitochondrial transport in Alzheimer's neurons. L Guo, H Du, S Yan, X Wu, G M Mckhann, J X Chen, S S Yan, 10.1371/journal.pone.0054914PLoS ONE. 82013e54914. [CrossRef</p>
<p>ABAD Directly Links A to Mitochondrial Toxicity in Alzheimer's Disease. J W Lustbader, 10.1126/science.1091230Science. 3042004</p>
<p>Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. D A Butterfield, B Halliwell, 10.1038/s41583-019-0132-6Nat. Rev. Neurosci. 202019</p>
<p>Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). J Zheng, 10.3892/ol.2012.928Oncol. Lett. 42012</p>
<p>J Nunnari, A Suomalainen, Mitochondria, 10.1016/j.cell.2012.02.035Sickness and in Health. 2012148</p>
<p>Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: Many pathways to neurodegeneration. D A Butterfield, S S Hardas, M L Lange, 10.3233/JAD-2010-1375J. Alzheimer's Dis. 202010</p>
<p>Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders. M D Berry, J. Psychiatry Neurosci. 292004</p>
<p>An inverse-Warburg effect and the origin of Alzheimer's disease. L A Demetrius, D K Simon, Biogerontology. 132012</p>
<p>The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. S Pavlides, D Whitaker-Menezes, R Castello-Cros, N Flomenberg, A K Witkiewicz, P G Frank, M C Casimiro, C Wang, P Fortina, S Addya, 10.4161/cc.8.23.10238Cell Cycle. 82009</p>
<p>Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization. L Pellerin, P J Magistretti, 10.1073/pnas.91.22.10625Proc. Natl. Acad. Sci. Natl. Acad. SciUSA199491</p>
<p>Cybrids in Alzheimer's disease: A cellular model of the disease. R H Swerdlow, J K Parks, D S Cassarino, D J Maguire, R S Maguire, J P Bennett, Jr, R E Davis, W D Parker, Jr, 10.1212/WNL.49.4.918Neurology. 491997</p>
<p>Retinal glial changes in Alzheimer's disease-A review. J A Fernandez-Albarral, E Salobrar-Garcia, R Martinez-Paramo, A I Ramirez, R De Hoz, J M Ramirez, J J Salazar, 10.1016/j.optom.2018.07.001J. Optom. 122019</p>
<p>Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases. A N Nilson, K C English, J E Gerson, T Barton Whittle, C Nicolas Crain, J Xue, U Sengupta, D L Castillo-Carranza, W Zhang, P Gupta, 10.3233/JAD-160912J. 552017Alzheimer's Dis</p>
<p>The Role of Mitochondria in Neurodegenerative Diseases: The Lesson from Alzheimer's Disease and Parkinson's Disease. G Monzio Compagnoni, A Di Fonzo, S Corti, G P Comi, N Bresolin, E Masliah, 10.1007/s12035-020-01926-1Mol. Neurobiol. 572020</p>
<p>Retinal Neurodegeneration in Diabetes: An Emerging Concept in Diabetic Retinopathy. M M Sachdeva, 10.1007/s11892-021-01428-xCurr. Diabetes Rep. 212021</p>
<p>Retinal neurodegeneration in age-related macular degeneration. C Barresi, J Chhablani, R Dolz-Marco, R Gallego-Pinazo, A Berni, F Bandello, E Borrelli, 10.1177/11206721231186166Eur. J. Ophthalmol. 2023. 11206721231186166</p>
<p>The retina: A window in which to view the pathogenesis of Alzheimer's disease. J Zhang, L Shi, Y Shen, 10.1016/j.arr.2022.101590Ageing Res. Rev. 772022. 101590</p>
<p>Effect of high glucose levels on amyloid beta production in retinas of spontaneous diabetes mellitus Otsuka Long-Evans Tokushima fatty rats. N Nagai, Y Ito, T Tanino, 10.1248/bpb.b14-00819Biol. Pharm. Bull. 382015</p>
<p>Platelet-generated amyloid beta peptides in Alzheimer's disease and glaucoma. M Inyushin, A Zayas-Santiago, L Rojas, Y Kucheryavykh, L Kucheryavykh, Histol. Histopathol. 342019</p>
<p>Beta-Amyloid Precursor Protein (betaAPP) Processing in Alzheimer's Disease (AD) and Age-Related Macular Degeneration (AMD). Y Zhao, S Bhattacharjee, B M Jones, J M Hill, C Clement, K Sambamurti, P Dua, W J Lukiw, 10.1007/s12035-014-8886-3Mol. Neurobiol. 522015</p>
<p>GSK3β-mediated tau hyperphosphorylation triggers diabetic retinal neurodegeneration by disrupting synaptic and mitochondrial functions. H Zhu, W Zhang, Y Zhao, X Shu, W Wang, D Wang, Y Yang, Z He, X Wang, Y Ying, 10.1186/s13024-018-0295-zMol. Neurodegener. 132018</p>
<p>Tau Accumulation, Altered Phosphorylation, and Missorting Promote Neurodegeneration in Glaucoma. M Chiasseu, Cueva, J L Vargas, L Destroismaisons, C Vande Velde, N Leclerc, A Di Polo, 10.1523/JNEUROSCI.3986-15.2016J. Neurosci. 362016</p>
<p>Diabetic Retinopathy: Pathophysiology and Treatments. W Wang, A C Y Lo, 10.3390/ijms19061816Int. J. Mol. Sci. 192018. 1816</p>
<p>Inflammation and its role in age-related macular degeneration. A Kauppinen, J J Paterno, J Blasiak, A Salminen, K Kaarniranta, 10.1007/s00018-016-2147-8Cell Mol. Life Sci. 732016</p>
<p>Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy. J H Wu, Y N Li, A Q Chen, C D Hong, C L Zhang, H L Wang, Y F Zhou, P C Li, Y Wang, L Mao, 10.15252/emmm.201810154EMBO Mol. Med. 122020. e10154</p>
<p>Januleviciene, I. A Review of Neovascular Glaucoma: Etiology, Pathogenesis, Diagnosis, and Treatment. D Urbonaviciute, D Buteikiene, 10.3390/medicina58121870202258Medicina</p>
<p>Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. P L Lip, A D Blann, M Hope-Ross, J M Gibson, G Y Lip, 10.1016/S0161-6420(00)00663-1Ophthalmology. 1082001</p>
<p>Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Q Kang, C Yang, 10.1016/j.redox.2020.101799Redox Biol. 372020. 101799</p>
<p>Oxidative Stress, and Blood Serum Nutrients in Various Types of Glaucoma: A Systematic Review. M Mlynarczyk, M Falkowska, Z Micun, I Obuchowska, J Kochanowicz, K Socha, J Konopinska, Diet, 10.3390/nu14071421Nutrients. 142022. 1421</p>
<p>Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration. K Kaarniranta, H Uusitalo, J Blasiak, S Felszeghy, R Kannan, A Kauppinen, A Salminen, D Sinha, D Ferrington, 10.1016/j.preteyeres.2020.100858Prog. Retin. Eye Res. 792020. 100858</p>
<p>Targeted pharmacotherapy against neurodegeneration and neuroinflammation in early diabetic retinopathy. K D Rolev, X S Shu, Y Ying, 10.1016/j.neuropharm.2021.108498Neuropharmacology. 1872021. 108498</p>
<p>MicroRNA-15b Targets VEGF and Inhibits Angiogenesis in Proliferative Diabetic Retinopathy. Y Yang, Y Liu, Y Li, Z Chen, Y Xiong, T Zhou, W Tao, F Xu, H Yang, S Yla-Herttuala, 10.1210/clinem/dgaa538J. Clin. Endocrinol. Metab. 1052020</p>
<p>Evaluation of vascular endothelial growth factor (VEGF) level in the tears and serum of age-related macular degeneration patients. M Shahidatul-Adha, E Zunaina, M N Aini-Amalina, 10.1038/s41598-022-08492-7Sci. Rep. 1244232022</p>
<p>The pathology associated with diabetic retinopathy. J Lechner, O E O'leary, A W Stitt, 10.1016/j.visres.2017.04.003Vision. Res. 1392017</p>
<p>The worldwide epidemic of diabetic retinopathy. Y Zheng, M He, N Congdon, Indian. J. Ophthalmol. 602012</p>
<p>Brain insulin signalling in metabolic homeostasis and disease. T Scherer, K Sakamoto, C Buettner, 10.1038/s41574-021-00498-xNat. Rev. Endocrinol. 172021</p>
<p>Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. L E Stoeckel, Z Arvanitakis, S Gandy, D Small, C R Kahn, A Pascual-Leone, A Pawlyk, R Sherwin, P Smith, F1000Research 20165353</p>
<p>Glucose control levels, ischaemic brain lesions, and hyperinsulinaemia were associated with cognitive dysfunction in diabetic elderly. H Umegaki, T Kawamura, N Mogi, T Umemura, A Kanai, T Sano, 10.1093/ageing/afn051Age Ageing. 372008</p>
<p>Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: A cohort study. L G Exalto, G J Biessels, A J Karter, E S Huang, W J Katon, J R Minkoff, R A Whitmer, 10.1016/S2213-8587(13)70048-2Lancet Diabetes Endocrinol. 12013</p>
<p>Prediction of dementia in people with diabetes. A.-M Tolppanen, 10.1016/S2213-8587(13)70091-3Lancet Diabetes Endocrinol. 12013</p>
<p>The type 2 diabetes-specific dementia risk score (DSDRS) is associated with frailty, cognitive and functional status amongst Mexican community-dwelling older adults. O Y Bello-Chavolla, C A Aguilar-Salinas, J A Avila-Funes, 10.1186/s12877-020-01776-5BMC Geriatr. 202020</p>
<p>Severe Diabetic Retinal Disease and Dementia Risk in Type 2 Diabetes. L G Exalto, G J Biessels, A J Karter, E S Huang, C P Quesenberry, R A Whitmer, 10.3233/JAD-132570J. Alzheimer's Dis. 422014</p>
<p>Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes. A Gasecka, D Siwik, M Gajewska, M J Jaguszewski, T Mazurek, K J Filipiak, M Postula, C Eyileten, 10.3390/jcm9092807J. Clin. Med. 2020, 9, 2807</p>
<p>Diabetic Retinopathy Predicts Risk of Alzheimer's Disease: A Danish Registry-Based Nationwide Cohort Study. F N Pedersen, L Stokholm, F Pouwer, K Hass Rubin, T Peto, U Frydkjaer-Olsen, A S Thykjaer, N Andersen, J Andresen, T Bek, 10.3233/JAD-215313J. Alzheimer's Dis. 862022</p>
<p>Association Between Diabetic Retinopathy and Cognitive Impairment: A Systematic Review and Meta-Analysis. D Cheng, X Zhao, S Yang, G Wang, G Ning, 10.3389/fnagi.2021.692911Front. Aging Neurosci. 136929112021</p>
<p>Dynamic Changes of Amplitude of Low-Frequency Fluctuations in Patients With Diabetic Retinopathy. X Huang, Z Wen, C X Qi, Y Tong, Y Shen, 10.3389/fneur.2021.611702Front. Neurol. 126117022021</p>
<p>The Relationship Between Diabetic Retinopathy and Cognitive Impairment. R R Crosby-Nwaobi, S Sivaprasad, S Amiel, A Forbes, 10.2337/dc12-2141Diabetes Care. 362013</p>
<p>MicroRNAs as biomarkers of diabetic retinopathy and disease progression. B Martinez, P V Peplow, Neural Regen. Res. 142019</p>
<p>Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J. Alzheimer's Dis. E Steen, B M Terry, E J Rivera, J L Cannon, T R Neely, R Tavares, X J Xu, J R Wands, S M De La Monte, 10.3233/JAD-2005-710720057</p>
<p>Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. S E Arnold, Z Arvanitakis, S L Macauley-Rambach, A M Koenig, H.-Y Wang, R S Ahima, S Craft, S Gandy, C Buettner, L E Stoeckel, 10.1038/nrneurol.2017.185Nat. Rev. Neurol. 142018</p>
<p>Alterations in glucose metabolism in patients with Alzheimer's disease. G S Meneilly, A Hill, 10.1111/j.1532-5415.1993.tb07458.xJ. Am. Geriatr. Soc. 411993</p>
<p>Insulin receptor in the brain: Mechanisms of activation and the role in the CNS pathology and treatment. I Pomytkin, J P Costa-Nunes, V Kasatkin, E Veniaminova, A Demchenko, A Lyundup, K.-P Lesch, E D Ponomarev, T Strekalova, 10.1111/cns.12866CNS Neurosci. Ther. 242018</p>
<p>Insulin receptors are widely distributed in the central nervous system of the rat. J Havrankova, J Roth, M Brownstein, 10.1038/272827a0Nature. 2721978</p>
<p>Amyloid beta oligomers induce impairment of neuronal insulin receptors. W Q Zhao, F G De Felice, S Fernandez, H Chen, M P Lambert, M J Quon, G A Krafft, W L Klein, 10.1096/fj.06-7703comFASEB J. 222008</p>
<p>Demonstration of insulin-specific mRNA in cultured rat retinal glial cells. A Das, B Pansky, G C Budd, Investig. Ophthalmol. Vis. Sci. 281987</p>
<p>Functions of insulin and insulin receptor signaling in retina: Possible implications for diabetic retinopathy. C E Reiter, T W Gardner, 10.1016/S1350-9462(03)00035-1Prog. Retin. Eye Res. 222003</p>
<p>. J Freiherr, M Hallschmid, W H Frey, 2nd</p>
<p>Intranasal insulin as a treatment for Alzheimer's disease: A review of basic research and clinical evidence. Y F Brunner, C D Chapman, C Holscher, S Craft, F G De Felice, C Benedict, CNS Drugs. 272013</p>
<p>. H B Schioth, S Craft, S J Brooks, W H Frey, 2nd</p>
<p>Brain insulin signaling and Alzheimer's disease: Current evidence and future directions. C Benedict, 10.1007/s12035-011-8229-6Mol. Neurobiol. 462012</p>
<p>Intranasal Insulin for Alzheimer's Disease. M Hallschmid, 10.1007/s40263-020-00781-xCNS Drugs. 352021</p>
<p>Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets. M N N Vieira, R A S Lima-Filho, F G De Felice, 10.1016/j.neuropharm.2017.11.014Neuropharmacology. 1362018</p>
<p>Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease. I Yildirim Simsir, U E Soyaltin, S Cetinkalp, 10.1016/j.dsx.2018.03.002Diabetes Metab. Syndr. 122018</p>
<p>Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. T Perry, N H Greig, 10.2174/1567205054367892Curr. Alzheimer Res. 22005</p>
<p>Inflammation in Glaucoma: From the back to the front of the eye, and beyond. C Baudouin, M Kolko, S Melik-Parsadaniantz, E M Messmer, 10.1016/j.preteyeres.2020.100916Prog. Retin. Eye Res. 832021. 100916</p>
<p>The pathogenesis of glaucoma in the interplay with the immune system. J Rieck, 10.1167/iovs.12-9781Investig. Ophthalmol. Vis. Sci. 542013</p>
<p>Trounce, I.A. Mitochondrial dysfunction in glaucoma and emerging bioenergetic therapies. S Lee, N J Van Bergen, G Y Kong, V Chrysostomou, H S Waugh, E C O'neill, J G Crowston, 10.1016/j.exer.2010.07.015Exp. Eye Res. 932011</p>
<p>Pathogenesis of Ganglion. N N Osborne, Cell Death" in Glaucoma and Neuroprotection: Focus on Ganglion Cell Axonal Mitochondria. 2008Amsterdam</p>
<p>One Age-Related Neurodegenerative Disease of the Brain. R Mancino, A Martucci, M Cesareo, C Giannini, M T Corasaniti, G Bagetta, C Nucci, Alzheimer Glaucoma, Disease, 10.2174/1570159X16666171206144045Curr. Neuropharmacol. 162018</p>
<p>Hypothesis of optineurin as a new common risk factor in normal-tension glaucoma and Alzheimer's disease. Y H Liu, T Tian, 10.1016/j.mehy.2011.06.040Med. Hypotheses. 772011</p>
<p>. M L Chalasani, D Balasubramanian, G Swarup, 10.1016/j.exer.2007.10.021Focus on molecules: Optineurin. Exp. Eye Res. 872008</p>
<p>Optineurin in neurodegenerative diseases. T Osawa, Y Mizuno, Y Fujita, M Takatama, Y Nakazato, K Okamoto, 10.1111/j.1440-1789.2011.01199.xNeuropathology. 312011</p>
<p>Links among glaucoma, neurodegenerative, and vascular diseases of the central nervous system. C Nucci, A Martucci, M Cesareo, F Garaci, L A Morrone, R Russo, M T Corasaniti, G Bagetta, R Mancino, Prog. Brain Res. 2212015</p>
<p>High Occurrence Rate of Glaucoma among Patients with Alzheimer's Disease. A U Bayer, F Ferrari, C Erb, 10.1159/000047976Eur. Neurol. 472002</p>
<p>No increased risk of developing Alzheimer disease in patients with glaucoma. L V Kessing, A G Lopez, P K Andersen, S V Kessing, 10.1097/IJG.0b013e31802b3527J. Glaucoma. 162007</p>
<p>Alzheimer's disease and vascular dementia: Record linkage study. T D Keenan, R Goldacre, M J Goldacre, 10.1136/bjophthalmol-2014-305863Br. J. Ophthalmol. 992015Associations between primary open angle glaucoma</p>
<p>Glaucoma Is Not Associated With Alzheimer's Disease or Dementia: A Meta-Analysis of Cohort Studies. W Zhao, X Lv, G Wu, X Zhou, H Tian, X Qu, H Sun, Y He, Y Zhang, C Wang, 10.3389/fmed.2021.688551Front. Med. 86885512021</p>
<p>Alzheimer's disease-related changes in diseases characterized by elevation of intracranial or intraocular pressure. P Wostyn, K Audenaert, P P De Deyn, 10.1016/j.clineuro.2007.10.011Clin. Neurol. Neurosurg. 1102008</p>
<p>Vitreous fluid levels of β-amyloid(1-42) and tau in patients with retinal diseases. S Yoneda, H Hara, A Hirata, M Fukushima, Y Inomata, H Tanihara, 10.1007/s10384-004-0156-xJpn. J. Ophthalmol. 492005</p>
<p>Association between glaucoma and the risk of Alzheimer's disease: A systematic review of observational studies. X H Xu, J Y Zou, W Geng, A Y Wang, 10.1111/aos.14114Acta Ophthalmol. 972019</p>
<p>Association between Open-Angle Glaucoma and the Risks of Alzheimer's and Parkinson's Diseases in South Korea: A 10-year Nationwide Cohort Study. J Y Moon, H J Kim, Y H Park, T K Park, E C Park, C Y Kim, S H Lee, Sci. Rep. 8111612018</p>
<p>Alzheimer's disease, and Parkinson's disease: An 8-year population-based follow-up study. I C Lin, Y H Wang, T J Wang, I J Wang, Y D Shen, N F Chi, L N Chien, Glaucoma, 10.1371/journal.pone.0108938PLoS ONE. 92014. e108938</p>
<p>Prevalence of glaucoma in hospitalized older adults with Alzheimer's disease. Can. A A Pelletier, M E Theoret, T Boutin, M J Kergoat, F Massoud, J Latour, C Chayer, H Kergoat, 10.1017/S0317167100016590J. Neurol. Sci. 412014</p>
<p>Age-Related Macular Degeneration. A Gheorghe, L Mahdi, O Musat, Rom. J. Ophthalmol. 592015</p>
<p>Age-related macular degeneration. L S Lim, P Mitchell, J M Seddon, F G Holz, T Y Wong, 10.1016/S0140-6736(12)60282-7Lancet. 3792012</p>
<p>Parallel findings in age-related macular degeneration and Alzheimer's disease. K Ohno-Matsui, 10.1016/j.preteyeres.2011.02.004Prog. Retin. Eye Res. 302011</p>
<p>Iron increases APP translation and amyloid-beta production in the retina. L Y Guo, O Alekseev, Y Li, Y Song, J L Dunaief, 10.1016/j.exer.2014.10.012Exp. Eye Res. 1292014</p>
<p>The complexities underlying age-related macular degeneration: Could amyloid beta play an important role? Neural Regen. S A Lynn, E Keeling, R Munday, G Gabha, H Griffiths, A J Lotery, J A Ratnayaka, 201712</p>
<p>Retinal thickness in Alzheimer's disease: A systematic review and metaanalysis. J Haan, F D Verbraak, P J Visser, F H Bouwman, Diagn. Assess. Dis. Monit. 62017Alzheimer's Dement</p>
<p>Increased risk of Alzheimer's disease among patients with age-related macular degeneration: A nationwide population-based study. L Y Wen, L Wan, J N Lai, C S Chen, J J Chen, M Y Wu, K C Hu, L T Chiu, P T Tien, H Lin, 10.1371/journal.pone.0250440PLoS ONE. 162021. e0250440</p>
<p>Novel chelators based on adamantane-derived semicarbazones and hydrazones that target multiple hallmarks of Alzheimer's disease. D Palanimuthu, Z Wu, P J Jansson, N Braidy, P V Bernhardt, D R Richardson, D S Kalinowski, 10.1039/C8DT01099DDalton Trans. 472018</p>
<p>Iron chelators inhibit amyloid-beta-induced production of lipocalin 2 in cultured astrocytes. D W Dekens, P P De Deyn, F Sap, U L M Eisel, P J W Naude, 10.1016/j.neuint.2019.104607Neurochem. Int. 1322020. 104607</p>
<p>Early age-related macular degeneration, cognitive function, and dementia: The Cardiovascular Health Study. M L Baker, J J Wang, S Rogers, R Klein, L H Kuller, E K Larsen, T Y Wong, 10.1001/archophthalmol.2009.30Arch. Ophthalmol. 1272009</p>
<p>Spectral-Domain OCT Measurements in Alzheimer's Disease: A Systematic Review and Meta-analysis. V T T Chan, Z Sun, S Tang, L J Chen, A Wong, C C Tham, T Y Wong, C Chen, M K Ikram, H E Whitson, Ophthalmology. 1262019</p>
<p>Macular Thickness Decrease in Asymptomatic Subjects at High Genetic Risk of Developing Alzheimer's Disease: An OCT Study. I Lopez-Cuenca, R De Hoz, E Salobrar-Garcia, L Elvira-Hurtado, P Rojas, J A Fernandez-Albarral, A Barabash, J J Salazar, A I Ramirez, J M Ramirez, 10.3390/jcm9061728J. Clin. Med. 92020. 1728</p>
<p>Retinal Ganglion Cell Complex in Alzheimer Disease: Comparing Ganglion Cell Complex and Central Macular Thickness in Alzheimer Disease and Healthy Subjects Using Spectral Domain-Optical Coherence Tomography. Z Farzinvash, M Abutorabi-Zarchi, M Manaviat, H Zare Mehrjerdi, 10.32598/bcn.2021.2040.1Basic Clin. Neurosci. 132022</p>
<p>Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. P K Iseri, O Altinas, T Tokay, N Yuksel, 10.1097/01.wno.0000204645.56873.26J. Neuroophthalmol. 262006</p>
<p>Reliability and validity of Cirrus and Spectralis optical coherence tomography for detecting retinal atrophy in Alzheimer's disease. V Polo, E Garcia-Martin, M P Bambo, J Pinilla, J M Larrosa, M Satue, S Otin, L E Pablo, 10.1038/eye.2014.51201428</p>
<p>Neuroimaging of retinal nerve fiber layer in AD using optical coherence tomography. D A Valenti, 10.1212/01.wnl.0000280584.64363.83Neurology. 692007. 1060</p>
<p>Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer's disease. C Y Cheung, Y T Ong, S Hilal, M K Ikram, S Low, Y L Ong, N Venketasubramanian, P Yap, D Seow, C L Chen, 10.3233/JAD-141659J. Alzheimer's Dis. 452015</p>
<p>Macular Thickness Measurements with Frequency Domain-OCT for Quantification of Retinal Neural Loss and its Correlation with Cognitive Impairment in Alzheimer's Disease. L P Cunha, L C Lopes, L V F Costa-Cunha, C F Costa, L A Pires, A L M Almeida, M L R Monteiro, 10.1371/journal.pone.0153830PLoS ONE. 112016. e0153830</p>
<p>Optical Coherence Tomography in Patients with Alzheimer's Disease: What Can It Tell Us? Eye Brain. A Song, N Johnson, A Ayala, A C Thompson, 10.2147/EB.S235238202113</p>
<p>A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. K L Thomson, J M Yeo, B Waddell, J R Cameron, S Pal, 10.1016/j.dadm.2015.03.00120151Alzheimer's Dement</p>
<p>The role of optical coherence tomography in Alzheimer's disease. L P Cunha, A L Almeida, L V Costa-Cunha, C F Costa, M L Monteiro, 10.1186/s40942-016-0049-4Int. J. Retin. Vitr. 2242016</p>
<p>Alzheimer's disease: A review of its visual system neuropathology. Optical coherence tomography-a potential role as a study tool in vivo. J P Cunha, N Moura-Coelho, R P Proenca, A Dias-Santos, J Ferreira, C Louro, A Castanheira-Dinis, 10.1007/s00417-016-3430-yGraefes Arch. Clin. Exp. Ophthalmol. 2542016</p>
<p>Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward. J Alber, D Goldfarb, L I Thompson, E Arthur, K Hernandez, D Cheng, D C Debuc, F Cordeiro, L Provetti-Cunha, J Den Haan, 10.1002/alz.12006202016Alzheimer's Dement</p>
<p>Alzheimer disease and cerebrovascular pathology: An update. K A Jellinger, 10.1007/s007020200068J. Neural Transm. 1092002</p>
<p>Optical coherence tomography angiography in Alzheimer's disease: A systematic review and meta-analysis. A Katsimpris, A Karamaounas, A M Sideri, J Katsimpris, I Georgalas, P Petrou, 10.1038/s41433-021-01648-1202136Eye</p>
<p>Evaluation of optical coherence tomography angiographic findings in Alzheimer's type dementia. M Bulut, F Kurtuluş, O Gözkaya, M K Erol, A Cengiz, M Akıdan, A Yaman, 10.1136/bjophthalmol-2017-310476Br. J. Ophthalmol. 1022018</p>
<p>Retinal microvascular attenuation in mental cognitive impairment and Alzheimer's disease by optical coherence tomography angiography. J Wu, X Zhang, G Azhati, T Li, G Xu, F Liu, 10.1111/aos.14381Acta Ophthalmol. 982020</p>
<p>Optical Coherence Tomography Angiography in Diabetes and Diabetic Retinopathy. J Chua, R Sim, B Tan, D Wong, X Yao, X Liu, D S W Ting, D Schmidl, M Ang, G Garhofer, 10.3390/jcm9061723J. Clin. Med. 92020. 1723</p>
<p>Factors Affecting Repeatability of Assessment of the Retinal Microvasculature Using Optical Coherence Tomography Angiography in Healthy Subjects. T H Lee, H B Lim, K Y Nam, K Kim, J Y Kim, 10.1038/s41598-019-52782-6Sci. Rep. 92019. 16291</p>
<p>Age and gender influence on foveal avascular zone in healthy eyes. F Gomez-Ulla, P Cutrin, P Santos, M Fernandez, M Abraldes, J M Abalo-Lojo, F Gonzalez, 10.1016/j.exer.2019.107856Exp. Eye Res. 1892019. 107856</p>
<p>Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. X Hadoux, F Hui, J K H Lim, C L Masters, A Pébay, S Chevalier, J Ha, S Loi, C J Fowler, C Rowe, Nat. Commun. 42272019</p>
<p>S S More, J M Beach, C Mcclelland, A Mokhtarzadeh, R Vince, 10.1021/acschemneuro.9b00331Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease. 201910</p>
<p>S Lemmens, J Van Eijgen, K Van Keer, J Jacob, S Moylett, L De Groef, T Vancraenendonck, De Boever, 10.1167/tvst.9.9.9Stalmans, I. Hyperspectral Imaging and the Retina: Worth the Wave? Transl. 20209</p>
<p>Retinal hyperspectral imaging in the 5xFAD mouse model of Alzheimer's disease. J K H Lim, Q.-X Li, T Ryan, P Bedggood, A Metha, A J Vingrys, B V Bui, C T O Nguyen, 10.1038/s41598-021-85554-2Sci. Rep. 112021</p>
<p>Early Detection of Amyloidopathy in Alzheimer's Mice by Hyperspectral Endoscopy. S S More, J M Beach, R Vince, 10.1167/iovs.15-17406Investig. Ophthalmol. Vis. Sci. 572016</p>
<p>The application of retinal fundus camera imaging in dementia: A systematic review. S Mcgrory, J R Cameron, E Pellegrini, C Warren, F N Doubal, I J Deary, B Dhillon, J M Wardlaw, E Trucco, T J Macgillivray, 20176Alzheimer's Dement</p>
<p>Microvascular network alterations in the retina of patients with Alzheimer's disease. C Y Cheung, Y T Ong, M K Ikram, S Y Ong, X Li, S Hilal, J A Catindig, N Venketasubramanian, P Yap, D Seow, 2014Alzheimer's Dement10</p>
<p>. Y T Ong, S Hilal, C Y Cheung, X Xu, C Chen, N Venketasubramanian, T Y Wong, M K Ikram, 10.1159/000363286Retinal vascular fractals and cognitive impairment. Dement. Geriatr. Cogn. Dis. Extra. 42014</p>
<p>Retinal biomarkers for Alzheimer's disease and vascular cognitive impairment and dementia (VCID): Implication for early diagnosis and prognosis. Geroscience. C Czako, T Kovacs, Z Ungvari, A Csiszar, A Yabluchanskiy, S Conley, T Csipo, A Lipecz, H Horvath, G L Sandor, 10.1007/s11357-020-00252-7202042</p>
<p>Protein and Imaging Biomarkers in the Eye for Early Detection of Alzheimer's Disease. S Fereshetian, J S Agranat, N Siegel, S Ness, T D Stein, M L Subramanian, 10.3233/ADR-210283J. Alzheimer's Dis. Rep. 52021</p>
<p>Association of Cognitive Function with Amyloid-beta and Tau Proteins in the Vitreous Humor. L M Wright, T D Stein, G Jun, J Chung, K Mcconnell, M Fiorello, N Siegel, S Ness, W Xia, K L Turner, J. Alzheimer's Dis. 682019</p>
<p>Promise and challenge: The lens model as a biomarker for early diagnosis of Alzheimer's disease. T Tian, B Zhang, Y Jia, Z Li, 10.1155/2014/826503Dis. Markers. 8265032014. 2014</p>
<p>Alzheimer's disease diagnosis by detecting exogenous fluorescent signal of ligand bound to Beta amyloid in the lens of human eye: An exploratory study. C Kerbage, C H Sadowsky, D Jennings, G D Cagle, P D Hartung, Front. Neurol. 4622013</p>
<p>Detection of Amyloid beta Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer's Disease. C Kerbage, C H Sadowsky, P N Tariot, M Agronin, G Alva, F D Turner, D Nilan, A Cameron, G D Cagle, P D Hartung, 10.1177/1533317513520214Am. J. Alzheimer's Dis. Other Demen. 302015</p>
<p>Diagnosing Diabetic Neuropathy: Something Old, Something New. I N Petropoulos, G Ponirakis, A Khan, H Almuhannadi, H Gad, R A Malik, 10.4093/dmj.2018.0056Diabetes Metab. J. 422018</p>
<p>Potential use of corneal confocal microscopy in the diagnosis of Parkinson's disease associated neuropathy. N N Che, H Q Yang, 10.1186/s40035-020-00204-3Transl. Neurodegener. 9282020</p>
<p>Corneal Confocal Microscopy: An Imaging Endpoint for Axonal Degeneration in Multiple Sclerosis. I N Petropoulos, S Kamran, Y Li, A Khan, G Ponirakis, N Akhtar, D Deleu, A Shuaib, R A Malik, 10.1167/iovs.17-22050Investig. Ophthalmol. Vis. Sci. 582017</p>
<p>Ocular Biomarkers of Alzheimer's Disease: The Role of Anterior Eye and Potential Future Directions. C Dehghani, S Frost, R Jayasena, C L Masters, Y Kanagasingam, 10.1167/iovs.18-24694Investig. Opthalmol. Vis. Sci. 592018</p>
<p>Pupil reaction to light in Alzheimer's disease: Evaluation of pupil size changes and mobility. D F Fotiou, C G Brozou, A B Haidich, D Tsiptsios, M Nakou, A Kabitsi, C Giantselidis, F Fotiou, 10.1007/BF03324716Aging Clin. Exp. Res. 192007</p>
<p>Pupil size as an indicator of cognitive activity in mild Alzheimer's disease. M El Haj, G Chapelet, A A Moustafa, C Boutoleau-Bretonniere, 202221</p>
<p>Pupil size reflects successful encoding and recall of memory in humans. M T Kucewicz, J Dolezal, V Kremen, B M Berry, L R Miller, A L Magee, V Fabian, G A Worrell, 10.1038/s41598-018-23197-6Sci. Rep. 849492018</p>
<p>Pupil response biomarkers distinguish amyloid precursor protein mutation carriers from non-carriers. S M Frost, Y Kanagasingam, H R Sohrabi, K Taddei, R Bateman, J Morris, T Benzinger, A Goate, C L Masters, R N Martins, 10.2174/15672050113109990154Curr. Alzheimer Res. 102013</p>
<p>Optic-nerve degeneration in Alzheimer's disease. D R Hinton, A A Sadun, J C Blanks, C A Miller, 10.1056/NEJM198608213150804N. Engl. J. Med. 3151986</p>
<p>Optic nerve head and nerve fiber layer in Alzheimer's disease. C S Tsai, R Ritch, B Schwartz, S S Lee, N R Miller, T Chi, F Y Hsieh, 10.1001/archopht.1991.01080020045040Arch. Ophthalmol. 1091991</p>
<p>Analysis of optic disk color changes in Alzheimer's disease: A potential new biomarker. M P Bambo, E Garcia-Martin, F Gutierrez-Ruiz, J Pinilla, S Perez-Olivan, J M Larrosa, V Polo, L Pablo, 10.1016/j.clineuro.2015.02.016Clin. Neurol. Neurosurg. 1322015</p>
<p>Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer's disease patients. S Lemmens, T Van Craenendonck, J Van Eijgen, L De Groef, R Bruffaerts, D A De Jesus, W Charle, M Jayapala, G Sunaric-Megevand, A Standaert, 10.1186/s13195-020-00715-1Alzheimers Res. Ther. 122020</p>
<p>Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods. instructions or products referred to in the content</p>            </div>
        </div>

    </div>
</body>
</html>